Index

A
“A2” see Piperazine Derivatives
AA see Alcoholics Anonymous
“Abbots” see Pentobarbital
Aboriginal People see Native Americans
Absenteeism from School
  bullying and, x, 295–296, 295(fn 12)
  Native Americans, 3(fn 1)
  secondhand tobacco exposure and, 221–222
  (see also: Learning; Schools)
Abstinence
  Alcoholics Anonymous and, 14(fn 16), 358,
    358(fn 48)
  as a form of relapse prevention, 342, 342(fn 32)
  from alcohol, 14(fn 16)
    acamprosate pharmacotherapy, 343
    disulfiram pharmacotherapy, 338, 343–344,
      344(fn 33)
    naltrexone pharmacotherapy, 344, 344(fn 34)
  from caffeine, 56(fn 22)
  from opiate analgesics, 345–346
  from tobacco/nicotine, 347–348
  primary prevention and, 324, 324(fn 5)
Abusible Psychotropic, vii(fig), vii(t)
  definition, vii(fig 1)
  (see also: Psychodelics; Psychodepressants;
    Psychostimulants)
Abusive Use see Patterns of Drug and
  Substance Use
“Abyssinian Tea” see Cathinone
Academic Achievement
  alcohol use and, 220, 21–22(t)
  cannabis use and, 221
dual diagnosis and, 291
MDMA use and, 221
(see also: Learning; Memory; Schools)
Academic Performance see Learning
(see also: Memory; Schools; Teachers)
Acamprosate
  combination therapy, 343
  common adverse effects, 343
  pharmacotherapy for alcohol abstinence
    maintenance, 343
Accidental Poisoning see Unintentional Poisoning
Acculturation Theory, 167–168
  North American adolescents of Hispanic descent
    and, 167–168
  related stress, 167–168
“Ace” see Amphetamine
Acetone, 6(t)
  brand/trade names, 6(t)
  common street names, 6(t)
  products containing, 32
  use to extract crude coca paste, 62(fn 34)
  (see also Volatile Solvents and Inhalants)
“Acid” see LSD
Acquired Immune Deficiency Syndrome
  associated with intravenous drug
    administration, 9
  associated with methamphetamine use by gays
    and bisexuals, 51(fn 16)
  rates of diagnosis among adolescent boys, 309
  (see also: Human Immunodeficiency Virus;
    Tridiagnosis)
Actiq® see Fentanyl
“Adam” see 3,4-Methylenedioxyamphetamine

1 This index contains all the major subject entries for the data included in this text. In order to facilitate its use, the following notations have been added in addition to page entries: (1) “fig” for figure; (2) “fign” for figure endnote; (3) “fn” for text footnote; (4) “t” for table; and (5) “tn” for table endnote. Street names for drugs and drug-related slang terms are denoted by quotation marks.

2 Some of the brand/trade names (denoted by ®), which are included in this index, are no longer licitly manufactured in North America (i.e., have been discontinued by the manufacturer because they have been replaced by a generic version or may have been officially withdrawn from use by FDA regulation). However, they remain available from other countries, or from illicit producers within North America, and are fairly easily obtained by means of purchase over the Internet. Therefore, we have included these drug names in this text and index.
Adderall® see Mixed Amphetamines
Addiction see Physical Dependence
“Addies” see Mixed Amphetamines
A-D/HD see Attention-Deficit/Hyperactivity Disorder

Adolescent
age-associated harm associated with drug and substance use, 320
attraction to particular drugs and substances of abuse, 320
definition, xiii(fn13)
protective factors from drug and substance use, 323
risk factors for drug and substance use, 323
(see also: Adolescent Boys; Adolescent Girls)

Adolescent Boys
binge drinking, 15–17
volatile solvent and inhalant poisoning, 38
(see also: Boys; North American Adolescents)

Adolescent Girls
binge drinking, 15–17
flunitrazepam use, 26(fn 30)
methamphetamine use, 45, 46(fn 8)
during pregnancy, 196
lesbian adolescent girls and, 46
mothers who use the drugs and substances of abuse
therapeutic use of family therapy, 350(fn 38)
recommendation for psychometric screening, 248
tobacco use, 117
underestimation of A-D/HD, 237(fn 18)
use of drugs and substances of abuse in comparison to boys, 117
(see also: Girls; Lesbian Adolescent Girls; North American Adolescents)

“Adolph” see Methadone
Adulterants
toxicity
cocaine and, 66, 66(fn 39)
opiate analgesics and, 9, 10, 12(tn)
used to “cut” drugs and substances of abuse, 66

Advertising
effects, 166–167
primary prevention and, 318(fn 1), 332
tobacco, 166, 167
(see also Food and Drug Administration, Regulations)

Afghanistan
source country for heroin, 7
use of opium for sedation or management of teething pain, 216(fn 36)

AIDS see Acquired Immune Deficiency Syndrome
“Airblasting”
definition, 35

Alaskan Natives
dual tobacco use and, 70(fn 49), 71(fn 51)
methamphetamine use and, 47
tobacco use and, 71(fn 51)
volatile solvent and inhalant use by children and adolescents and, 34(fn 42)
(see also: Inuit; Native Americans; North American Adolescents of Native Descent)

Alcohol, 6(t), 12–25
abstinence
pharmacotherapy for maintenance, 343–345
reasons for, 14(fn 16)
abuse, 263(t)
advertising, 166–167
alcoholism, 23–24, 263(t)
A-D/HD and, 237
characteristics, 23, 263(t)
cocaine compulsive use and, 68(fn 44)
definition, 23, 263(t)
genesis of male alcoholism and, 127
incidence, 23–24
North American adolescents of Native descent, 24(fn 26)
natural history of alcoholism and, 128–129
natural history of drug use from adolescence to the mid-30s and, 129–130
signs and symptoms, 23, 263(t)
Asian flush, 13
binge drinking, 15–17
characteristics of adolescent binge drinkers, 17
definition, 15
during pregnancy, 183, 241–242
high risk adolescent groups
bisexual boys, 17
lesbian and bisexual girls, 17
students of Hispanic descent, 17
incidence, 16–17, 183
biological theory of sensation seeking and, 122, 123, 124
“blackouts”, 23, 232
blood alcohol concentration and effects, 19(t), 24(fig)
chronobiological control theory and, 120–121
cirrhosis and, xiii(fn 9)
college students and, 17, 17(fn 19, 20), 20, 22, 22(fn 25)
combined use with cannabis, 175(fn 12)
combined use with flunitrazepam, 26(fn 30)
combined use with GHB, 30, 32
common street names, 6(t)
concentration see blood alcohol concentration and effects
craving see psychological dependence
date rape see sexual assault
death and, 13(fn 15), 18(fn 21), 20
delirium tremens, 24–25
dependence see alcoholism
drinking and driving, 22, 22(fn 24), 24(fig), 248(fn 2)
*ego-self theory of substance dependence* and, 137
energy drink use and, 17–18
excretion in breast milk, 204(t)
FAS / FASD, 18, 20, 179, 183–188
craniofacial characteristics, 185(fig)
diagnostic code, 186(t)
incidence, 20, 187(t)
long-term sequelae, 187, 241
prevalence of associated abnormalities, 184(t)
screening, 187–188
treatment recommendations, 188, 188(fn 17)
GHB overdosage and, 32
general pharmacology, 18–25
harmful drinking, 263(t)
hazardous drinking, 263(t), 264(tn a, b)
heavy (episodic) drinking, 263(t)
incidence of drinking while on school property, 15
injuries and, 20, 248(fn 2)
legal age for drinking, 14
*life process program theory of natural recovery* and, 147
mechanism of action, 18
GABA receptor complex and, 23(fig)
*natural history of alcoholism* and, 128–129
*natural history of drug use from adolescence to the mid-30s* and, 129–130
patterns of use and increasing harm, 15(fig)
physical assaults and, 20
physical dependence, 21(t), 22
*predictive model of adolescent use of the drugs and substances of abuse* and, 150
prevalence of having been drunk, 15
preventable death and, 13(fn 15)
*problem behavior theory: a field theory of problem drinking* and, 161
psychological dependence, 21(t), 22–23
rape see sexual assault
*right-brain model of adolescent substance abuse* and, 141–142
reasons for use, 12
risky drinking, 264(t)
screening for prenatal exposure, 199
self-medication and, 137, 138, 295, 298, 311(t)
sexual assault, 12, 20, 21–22(t)
*somatosensory affectional deprivation theory* and, 121, 122
teratogenesis and, 173, 179, 182–188
ability to cross the placental barrier, 179–180
similarity to toluene embryopathy, 184, 192
*theoretical framework of developmental stages in adolescent drug involvement* and, 154
*theory of drug subculture* and, 152, 153
tolerance, 22
toxicity
acute and chronic toxicities, 18(fn 21), 21–22(t)
homicide, 13, 22(t)
motor vehicle crashes, 13, 24(fig)
direct physical harm, 13
hospitalizations of adolescents, 18(fn 21)
neurotoxicity, 232
teratogenesis and, 173
(see also FAS / FASD)
mental harm, 13
effects on learning, 18, 227, 227(fn 5), 228, 230
state-dependent learning and, 231, 231(fn 11)
effects on memory, 231, 232–233
mental disorders associated with use, 299(t)
psychosis, 21(t), 22(tn a)
preventable death, 13(fn 15), 18(fn 21), 20
social harm, 13
motor vehicle crashes, 13, 24(fig)
unintentional childhood poisonings, 215
use by children and adolescents, 13–18
during pregnancy, 182–183
high school students, 14–15
initial use, 13
North American adolescents of Native descent, 173
use by college students, 20, 20(fn 23), 21
Wernicke-Korsakoff syndrome and, 21–22(t), 22(tn a, b), 25, 232
withdrawal syndrome, 22, 24–25
Alcohol (Continued)
delirium tremens, 24–25
management, 25, 25(fn 28), 341–342
self-management with GHB, 29
(see also: Alcoholism; Alcohol Use Disorders; Sedative-Hypnotics)
Alcohol-Containing Mouthwashes, 215
Alcoholic Blackout see Alcoholism
(see also Memory)
Alcoholic Delirium see Delirium Tremens
Alcoholics Anonymous (AA), 357–359
abstinence, 14(fn), 358, 358(fn 48)
cognitive-behavioral theory of adolescent chemical dependency and, 148, 150
limitations, 357(fn 46), 358(fn 49)
number of meetings attended, 358(fn 49)
relapse prevention factors, 358
Serenity Prayer, 357(fn 46)
social form of treatment, 358, 358(fn 47)
spiritual characteristics, 357(fn 46)
twelve steps
list, 358(t)
twelve-step treatment program
biopsychosocial model of adolescent susceptibility to a substance abuse disorder and, 166
twelve steps

theory of object relations and adolescent compulsive drug use and, 143

Alcoholism, 23–24
A-D/HD and, 237
“blackouts”, 23, 232
characteristics, 23
cocaine compulsive use and, 68(fn 44)
definition, 23, 263(t)
delirium tremens, 24–25
detection by means of laboratory tests, 250(fn 4)
detection among adolescents by means of quick-screen psychometric tests
AUDIT, 261–262, 262(t), 265–264
AUDIT-C, 265–267, 266(t)
B-MAST, 267–268, 268(t)
CAGE, 268–270, 269(t)
CRAFFT, 272–273, 273(t)
MAST, 278–280, 278(fn 22), 279(t)
POSIT, 280–281, 281(t)
RAPS4, 281–282, 282(t)
RAPI, 282–284, 283(t)
SMAST, 284–285, 285(t)
T-ACE, 285–286, 286(t)
TWEAK, 286–288, 287(t)
genesis of male alcoholism and, 127
incidence, 23–24
North American adolescents of Native descent, 24(fn 26)
natural history of alcoholism and, 128–129
natural history of drug use from adolescence to the mid-30s and, 129–130
signs and symptoms, 23
(see also: Alcohol; Alcohol Use Disorders)
Alcohol-Like Disinhibitory Euphoria
benzodiazepines and, 25
GHB and, 29
phencyclidine and, 110
volatile solvents and inhalants, and 32, 37, 38
Alcohol-Related Neurodevelopmental Disorder, 185–186
(see also FAS / FASD)
Alcohol-Related Birth Defects, 185–186
(see also FAS / FASD)
Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), 259–261
development by the WHO, 259–260
domains, 260
reliability, 261
scoring, 260
sensitivity, 260–261
specificity, 260–261
validity, 261
Alcohol Use Disorders (AUDs)
concealment of use, 245, 246(fn a), 256–258, 256(fn 11), 257(fn 12)
North American adolescents of African descent, 245
definitions, 263–264(t)
detection among adolescents by means of quick-screen psychometric tests
AUDIT, 261–262, 262(t), 265–264
AUDIT-C, 265–267, 266(t)
B-MAST, 267–268, 268(t)
CAGE, 268–270, 269(t)
CRAFFT, 272–273, 273(t)
MAST, 278–280, 278(fn 22), 279(t)
POSIT, 280–281, 281(t)
RAPS4, 281–282, 282(t)
RAPI, 282–284, 283(t)
SMAST, 284–285, 285(t)
T-ACE, 285–286, 286(t)
TWEAK, 286–288, 287(t)
screening, 245–248
flowchart, 247(fig)
importance, 246–248
missed diagnoses, 246(t)
(see also: Alcohol; Alcoholism)
Alcohol Use Disorders Identification Test
(AUDIT), 261–262, 262(t), 264–265
detection of AUDs, 261–265
development by the WHO, 261
emergency department use, 261
international use, 261
recommendations, 265
reliability, 264
scoring, 261–262, 262(t)
sensitivity, 262, 264
specificity, 262, 264
validity, 264
transcultural, 265(fn 14)
(see also AUDIT-C)
Alcohol Use Disorders Identification Test–
Consumption (AUDIT-C), 265–267, 266(t)
detection of AUDs, 265
emergency department use, 266
reliability, 267
scoring, 265–266, 266(t)
sensitivity, 266–267
specificity, 266–267
validity, 267
(see also AUDIT)
ALERT, 329
Alertec® see Modafinil
Alfenta® see Alfentanil
Alfentanil
excretion in breast milk, 208(t)
(see also Opiate Analgesics)
“Alpha-ET” see Alpha-ethyltryptamine
Alpha-ethyltryptamine, 90(t)
Alpha-methyltryptamine, 90(t)
Alprazolam, 5(t)
benzodiazepine withdrawal syndrome and, 28
brand/ trade names, 5(t)
common street names, 5(t)
respiratory depression and, 29
teratogenic risk and, 189
(see also Benzodiazepines)
Amanita muscaria, 90(t)
Ambien® see Zopidem
American Indians see Native Americans
American Snuff, 81(t)
(see also Tobacco, Smokeless)
American Snus see American Snuff
Amnesia see Memory
Amobarbital
brand/ trade names, 5(t)
state-dependent learning and, 231, 231(fn 11)
(see also Barbiturates)
Amotivational Syndrome, ix, 228
alternative hypothesis, 228(fn 7)
barbiturates and, 228
cannabis and, 103(t, tn a), 105, 105(fn 23), 228–229
(see also Learning)
“AMP” see “Fry”
Amphetamine see Amphetamines
Amphetamine-Like Psychedelics, 87, 89–94
classification, 89(fig), 90–91(t)
common street names, 90(t)
generic names, 90(t)
MDMA
ease of obtaining by adolescents, 91
source countries, 91
use
among adolescents, 91–92
highest use, 91–92
of African descent, 91
among high school students, 91
among homeless youth, 91
among gay youth, 91, 92
circuit parties and, 92
correlation with unprotected sex, 92
among lesbian youth, 91, 92
clubbing and, 89
factors associated with, 91
history of, 89
raves and, 88, 89
(see also: MDMA; Psychedelics)
Amphetamines, 43–53
amphetamine salts, 44(tn b, c)
biological theory of sensation seeking and, 122, 124
brand/ trade names, 44(t)
common street names, 44(t)
excretion in breast milk, 204(t)
general pharmacology, 47–53
list, 44(t)
mechanism of action, 48, 49(fig)
indirect-acting psychostimulants, 48
natural history of drug use and, 128
overdose, 51, 52–53
fatalities, 53
management, 53
median lethal dose, 53
Amphetamines (Continued)
psychostimulants commonly used by children and adolescents, 45(fig)
reasons for use, 48, 226, 226(fn 4)
“run”, 50, 50(fn 12)
relationship to ephedrine, 46(fn 5), 47–48
screening for prenatal exposure, 199
state-dependent learning and, 231, 231(fn 11)
sympathomimetic actions, 47–48, 47–48(fn 9)
theoretical framework of developmental stages in adolescent drug involvement and, 154
tolerance, 52
toxicity, 48–53
acute toxicities, 48–50
aggressive/violent behavior, 48–49, 48(fn 11)
homicide, 52
mental disorders associated with use, 299(t)
chronic toxicities, 50–51
cardiovascular disorders, 50, 50(fn 15)
impaired executive functioning, 50(fn 13)
“meth mouth”, 50(fn 14)
intravenous use and, 49–50, 51(fn 16)
neurotoxicity, 48(fn 10), 50, 50(fn 13)
impaired executive functioning, 50(fn 13)
Parkinsonian-like effects, 50(fn 13)
physical dependence, 52
psychological dependence, 52
psychosis, 49, 50, 51
management, 51
punding, 50, 51
trends in use, 43, 45–46
use as performance enhancers, 48
withdrawal syndrome, 52, 52(fn 18)
factors affecting, 48
(see also: individual amphetamines; Psychostimulants)

“Angel Dust” see Phencyclidine
Anorex-SR® see Phendimetrazine
Antabuse® see Disulfiram
Anterograde Amnesia see Memory
Anticonvulsants, vii(fig 1), viii(t)
Antidepressants, vii(fig 1), viii(t)
Antiparkinsonians, vii(fig 1), viii(t)
Antipsychotics, vii(fig 1), viii(t)
Antisocial Personality Disorder
A-D/HD and, 237
natural history of drug use and, 128
Appgar Score
clinical utility, 190(fn 18)
effect of opiate analgesic use by mothers, 190
scoring criteria, 191(t)
ARBD see Alcohol-Related Birth Defects
ARND see Alcohol-Related Neurodevelopmental Disorder
Ariva® see Tobacco, Smokeless, Lozenges
Armoflin®, 44(t)
(see also Psychostimulants)
Assessment see Detecting Adolescent Use of the Drugs and Substances of Abuse
ASSIST see Alcohol, Smoking, and Substance Involvement Screening Test
Ativan® see Lorazepam
Atomoxetine, 44(t), 240
(see also Psychostimulants)
Attention see Learning
Attention-Deficit/Hyperactivity Disorder, 237–241, 293(fn 10)
aggressive behavior and, 293(fn 9)
 alcohol use and, 293
as an antecedent of SUDs, 293
cocaine use during pregnancy and, 194
conduct disorder and, 293–294
dependence on cocaine and, 137
diversion of prescribed drugs by children and adolescents and, ix, 43, 86,
237–238, 293
dual diagnosis and, 292–293, 292(fn 8)
adverse consequences of, 293
suicide, 293
therapeutic use of family therapy, 350(fn 38)
etiology, 237
FAS / FASD and, 237
illicit drug and substance use and, 237–238
incidence, 237, 237(fn 18), 292
learning impairment and, 238–239
management
non-pharmacological approaches, 240
psychostimulants, 43, 226, 239, 239(fig), 293
impairment of cognitive performance, 239(fig)
lisdexamfetamine used in treatment of, 43
methylphenidate used in treatment of, 43, 226, 231, 240, 293
mixed amphetamines used in treatment of, 43, 293
misdiagnosis, 240, 240(fn 19, 20)
problems not fully identified until child enters school, 221
secondhand tobacco smoke exposure and, 213
self-medication and, 137
selling of own prescriptions, ix, 43, 86, 237–238, 293
signs and symptoms, 238(t)
tobacco smoking and, 69, 198, 292–293, 292(fn 8)
toluene embryopathy and, 192
(see also Dual Diagnosis)
AUDs see Alcohol Use Disorders
AUDIT see Alcohol Use Disorders Identification Test
Autocide see Suicide
Autoerotic Stimulation
problems not fully identified until child enters school, 221
Ayahuasca, 94

B
BAC see Blood Alcohol Concentration
“Baccy” see Tobacco
“Baggering”
definition, 35
“Balling”
definition, 65(fn 37)
Banisteriopsis caapi, 94
Barbiturates, viii(t), 5(t)
amotivational syndrome and, 228
biological theory of sensation seeking and, 122
brand/trade names, 5(t)
excretion in breast milk, 204(t)
GABA receptor complex and, 23(fig)
list, 5(t)
pharmacological management of seizure disorders, 230–231, 231(fn 10)
street names, 5(t)
teratogenic risk, 188–189
theory of adolescent psychological individuation and, 139, 140
(see also Sedative-Hypnotics)
“Bath Salts” see Mephedrone
“BC Bud” see Cannabis
“BD” see 1,4-Butanediol
Beer see Alcohol
Belladonna Alkaloids, 87(fn 1)
“Belushi”, 62(fn 33)
“Bennies” see Amphetamines
Benzene, 6(t)
products containing, 32
(see also Volatile Solvents and Inhalants)
Benzodiazepines, vii(t), 5–6(t), 25–29
alcohol-like disinhibitory euphoria, 25
brand/trade names, 5–6(t)
ease of obtaining by adolescents, 26
emergency department admission and, 26
excretion in breast milk, 205(t)
general pharmacology, 26–29
list, 5(t)
mechanism of action, 26–27, 27(fig)
GABA receptor complex and, 23(fig), 27, 27(fig)
most popular among high school students, 26
overdose, 29
fatalities, 29
treatment, 29, 340–341
pharmacological management of seizure disorders, 230–231, 231(fn 10)
“pharming”, 26
physical dependence, 27
history of alcoholism and, 28
psychological dependence, 27
receptors, 26–27, 27(fig)
reasons for use, 25–26, 25(fn 28)
screening for prenatal exposure, 199
self-medication and, 298, 311(t)
results, 26–27, 27(fig)
sources for children and adolescents, 26
street names, 5–6(t)
teratogenic risk, 189
tolerance, 28
indicators of, 28
toxicity, 27
adverse effects on memory, 231, 233–234
use by Canadian adolescents and young adults, 26
use by children and adolescents, 25–26
use by high school students, 26
use for management of the alcohol withdrawal syndrome, 25, 25(fn 27,28)
Benzodiazepines (Continued)
use for management of the GABA withdrawal syndrome, 31–32
withdrawal syndrome, 28
factors contributing to occurrence and severity, 28, 28(fn 31,32)
management, 28
signs and symptoms, 28
(see also Sedative-Hypnotics)
Benzphetamine, 44(t)
(see also Amphetamines)
Betel Cutch, 44(t)
(see also Psychostimulants)
“Betel Nut” see Betel Cutch
“Betel Quid” see Betel Cutch
Bidis, 72–73
flavoring, 73
nicotine content, 73
reasons for use by adolescents, 73
source country, 73
use by North American adolescents, 73
(see also: Nicotine; Tobacco)
“Big Sal” see Salvia divinorum
“Big T” see Pentazocine
Binge Drinking, 15–17
characteristics of adolescent binge drinkers, 17
college students and, 17, 17(fn 19, 20)
definition, 15
during pregnancy, 183, 241–242
effects on intelligence quotient, 241–242
learning problems and, 241–242
gender effects, 15–17
high risk adolescent groups
bisexual boys, 17
lesbian and bisexual girls, 17
students of Hispanic descent, 17
incidence, 16–17, 183
prospective memory impairment and, 232–233
volatile solvent and inhalant use and, 17
(see also: Alcohol; Alcoholism; Alcohol Use Disorders)
Biological Theory of Sensation Seeking, 122–124
assumptions, 122
hypotheses, 122–123
risky behavior paradigm and, 123
sensation seekers, 122–124
Biopsychosocial Model of Adolescent Susceptibility to a Substance Abuse Disorder, 164–166
application to treatment, 165–166
dual diagnosis and, 166
use with other treatment approaches, 166
interacting causal factors, 164–165
stages, 165
Birth Defects see Teratogenesis
Bisexual Adolescent Boys and Young Adults
attendance at circuit parties, 30
binge drinking and, 17
GHB use and, 29, 30
methamphetamine use and, 45, 51(fn 16)
increased risk for human immunodeficiency virus infection, 51(fn 16)
increased risk for related neurotoxicity, 48(fn 10)
MDMA use and, 91–92
smokeless tobacco use and, 70(fn 48)
(see also: Circuit Parties; Club Drugs; Gays; Human Immunodeficiency Virus)
Black & Mild® see Tobacco Cigarillos
“Blackouts” see Alcohol
(see also: Alcoholism; Memory)
Black Tar Heroin
concentration/purity, 8(fn 7)
source country, 7
use by North American adolescents of Hispanic descent, 7(fn 5)
(see also: Heroin)
Blood Alcohol Concentration
associated physical and psychological effects, 19(t)
drinking and driving, 24(fig)
(see also: Alcohol)
“Blow” see Cocaine
“Blueberries” see Mixed Amphetamines
“Blues” see Diazepam
“Blue Stars” see Lysergic Acid Amide
“Blunts”
definition, 98(fn 11)
(see also: Marijuana)
B-MAST see Brief Michigan Alcoholism Screening Test
“Bocca” see Ibogaine
“Boga” see Ibogaine
“Bombers” see Amphetamines
Bontril® see Phendimetrazine
“Booze” see Alcohol
Boys
caffeine consumption, 56
delinquent behavior, 294
smokeless tobacco use, 70
tobacco smoking, 70
volatile solvent and inhalant use, 34, 34(fn 39)
(see also: Adolescent Boys; Children)
Brand/Trade Names
amphetamines, 44(t)
barbiturates, 5(t)
benzodiazepines, 5–6(t)
miscellaneous psychostimulants, 44(t)
miscellaneous sedative-hypnotics, 6(t)
opiate analgesics, 5(t)

Breast-Feeding, 200–201
exposure to HIV, 201(fn 26), 202(fig)
factors affecting effects of exposure, 202
limitations of available data/studies, 202
recommendations to minimize, 202–203
Hispanic descent and, 201(fn 25)
rates 200–201, 201(fn 25)
(see also Breast Milk)

Breast Milk
alcohol and, 204(t)
amphetamines and, 204(t)
barbiturates and, 204(t)
benzodiazepines and, 205(t)
caffeine and, 205(t)
cannabis (tetrahydocannabinol) and, 205(t)
carisoprodol and, 206(t)
chloral hydrate and, 206(t)
cocaine and, 206(t)
colostrum, 210(tn a)
foremilk, 210(tn a)
meperidamate and, 207(t)
neonatal daily consumption, 210(tn a)
nicotine and, 208(t)
opiate analgesics and, 208(t)
phencyclidine and, 209(t)
zopiclone and, 210(t)
excretion of drugs and substances of abuse into, 204–210(t)
(see also Breast-Feeding)

“Brew” see Alcohol
Brief Michigan Alcoholism Screening Test
(B-MAST), 267–268, 268(t)
detection of AUDs, 267
recommendations, 268
scoring, 267, 268(t)
sensitivity, 267
specificity, 267
validity, 267–268
(see also: MAST; SMAST)

“Brigham Tea” see Ephedrine

Bromazepam, 5(t)
brand/trade names, 5(t)
(see also Benzodiazepines)
“Bromo” see 4-Bromo-2,5-dimethoxyphenethylamine
4-Bromo-2,5-dimethoxyphenethylamine, 90(t)
“Brown” see Heroin
“Bufo” see 5-Hydroxy-N,N-dimethyltryptamine
Bufotenine see 5-Hydroxy-N,N-dimethyltryptamine
Buprenex® see Buprenorphine
Buprenorphine, 5(t)
aid to opiate analgesic detoxification, 338
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
management of opiate analgesic dependence
during pregnancy, 191
unintentional childhood poisonings, 215
(see also Opiate Analgesics)
“Businessman’s Lunch” see N,N-Dimethyltryptamine
Butabarbital, 5(t)
brand/trade names, 5(t)
(see also Barbiturates)
Butalbital, 5(t)
combination product, 6(tn f)
(see also Barbiturates)
Butane, 6(t)
common street names, 6(t)
laryngeal edema/spasm and, 39
nonhalogenated hydrocarbons, 39(fn 45)
use related fatality, 38, 39
use to extract crude coca paste, 62(fn 34)
(see also Volatile Solvents and Inhalants)
1,4-Butanediol, 29(fn 33)
(see also GHB)
Butisol® see Butabarbital
Butorphanol, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
(see also Opiate Analgesics)
“Buttons” see Mescaline
“Butts” see Cigarettes

C
“C” see Cocaine
“Cactus” see Mescaline
Cafestol, 57(fn 25)
(see also Coffee)
Caffeine, 44(t, tn), 53–61
abstainers, 56(fn 22)
caffeinated soft drinks, 53, 54–55(t), 56
caffeinism, 59
chocolate and, 53, 55(t)
cholesterol and, 57(fn 25)
coffee and, 53
decaffeinated, 56(tn b)
cola beverages and, 53
Coca-Cola®, 53(fn 20)
content, 54(t)
FDA limit, 56(tn c)
combined use with nicotine (tobacco cigarettes), 175(fn 12)
content of selected foods and beverages, 54–55(t)
diuretic effect, 57, 57(fn 24)
energy drinks
alcohol use and, 57
content, 54–55(t), 55
increasing sale and use, 56–57
ergogenic effects, 57–58
excretion in breast milk, 205(t)
food products and, 55(t)
general pharmacology, 57–61
ergogenic effects, 57–58
hypoanalgesic effects, 58
headache relief and, 57
insomnia and, 58, 58(fn 27)
intoxication, 59
major sources for children and adolescents, 53, 56
mechanism of action, 58, 59(fig)
adenosine antagonism, 58, 58(fn 27)
indirect acting psychostimulant, 58
natural sources, 53, 53(fn 19)
nutritional supplements and, 55(tn)
physical dependence, 60–61, 61(fn 29)
psychological dependence, 60–61, 61(fn 29)
psychostimulants commonly used by children and adolescents, 45(fig)
reasons for use, 56, 226
stimulation of the respiratory center, 57
teas and, 53, 54(t)
teratogenesis and, 192–193
tolerance, 60, 61
toxicities, 58–61
acute toxicity, 59–60
caffeinism, 59
excessive daytime sleepiness, 59–60
insomnia, 58, 58(fn 27)
intoxication, signs and symptoms, 59
mental disorders associated with use, 299(t)
chronic toxicity, 60–61
cancer, 60
diabetes, 58(fn 26)
teratogenesis, 60, 192–193
recommendations for limited caffeine consumption during pregnancy, 60, 60(fn 28)
withdrawal syndrome, 56(fn 21), 59, 60, 61
signs and symptoms, 61, 61(fn 31)
(see also Psychostimulants)
Caffeinism, 59–60
definition, 59
(see also Caffeine)
“Caffy” see Coffee
CAGE, 268–270, 269(t)
detection of AUDs, 268
discussion, 270
negative predictive value, 269
positive predictive value, 269
reliability, 270
scoring, 268, 269(t)
sensitivity, 268–269, 270(t)
specificity, 268–269, 270(t)
validity, 269–270
California
domestic production of cannabis, 97, 98
hydrocodone use, 4
legal use of medical marijuana, 102(t, tn)
“Cambodian Red” see Cannabis
Camel Orbs® see Tobacco, Smokeless, Pellets
Camel Snus® see Tobacco, Smokeless, American Snuff
Camel Sticks® see Tobacco, Smokeless, Twisted Sticks
Camel Strips® see Tobacco, Smokeless, Film Strips
Campral® see Acamprosate
Canada
Aboriginal Canadian youth
ceremonies and rituals, 159(fn 13)
_ego-self theory of substance dependence_ and, 138
pentazocine abuse, 340
poverty level, 3(fn 1)
pregnancy and ethical/legal issues, 175(fn 11)
school drop-out rates, 3(fn 1)
teratogenesis risk, 172–173
use of volatile solvents and inhalants, 34(fn 42), 36
alcohol
legal age for drinking, 14
benzodiazepine use by adolescents, 26
caffeine
consumption patterns, 56
recommendations for maximum daily
consumption, 56
for pregnant adolescents, 60, 60(fn 28)
cannabis
“grow ops”, 98(fn 9)
high potency, 98, 98(fn 9)
medical use, 102(tn)
production, 97
source country, 98, 98(fn 9)
use by adolescents and young adults, 99
cocaine use by adolescents and young adults, 62
marijuana see cannabis
MDMA use, 91
nabilone, 90(tn a)
pentazocine
intravenous abuse by Aboriginal adolescents
and young adults, 340
unavailability of combination pentazocine/
naloxone tablets, 340
source country for cannabis, 98, 98(fn 9)
sourc country for kretex, 73
source country for MDMA, 91
Canadian Aborignals see Native Americans
(see also Canada, Aboriginal Canadian Youth)
“Cancer Stick” see Cigarettes
Cannabinoids
anandamide, 100(fn 16)
dronabinol, 90(tn a)
mechanism of action, 100–101
nabilone, 90(tn a)
THC, 97, 100
(see also: Endocannabinoid System; THC)
Cannabis, 90(t), 97–108
amotivational syndrome and, 103(t, tn a), 105,
105(fn 23), 228–229
cannabinoids, 100
dronabinol, 90(tn a)
nabilone, 90(tn a)
tetrahydrocannabinol, 97, 100
concentrations, 97, 98, 98(fn 12)
cash crops, 97–98
combined use with alcohol, 175(fn 12)
combined use with flunitrazepam, 26(fn 30)
ease of obtaining by adolescents, 99
effects on driving see toxicity,
motor vehicle crashes
elimination in regular long-term users, 107
endocannabinoid system, 100–101
endogenous agonists, 100(fn 16)
receptors, 101
excretion in breast milk, 205(t)
female plants, 97
general pharmacology, 100–108
“grow op”
definition, (98(fn 9)
secondhand smoke exposure and, 211
mechanism of action, 100–101
receptors, 101
memory impairment and, xii(fn 9, 10)
methods of use, 101–102
edible products, 101
smoking, 101, 102
vaporizing, 101–102
physical dependence, 108, 108(fn 32)
production, 97
domestic, 97–98
cash crop, 97–98
source country, 98, 98(fn 9)
screening for prenatal exposure, 199
self-medication and, 300, 304, 311(t)
sinsemilla, 97
species, 97, 97(fn 8)
synesthesia, 100
teratogenesis and, 104, 173
THC concentration, 97–98, 98(fn 12)
toxicities
acute, 102, 103(t)
motor vehicle crashes, 104, 106–107,
106–107(fn 30)
combined use with alcohol and, 105,
106(fn 29)
suicide and, 105(fn 24), 106
chronic, 102, 102(t), 105(fn 23)
amotivational syndrome, 103(t, tn a), 105,
105(fn 23), 228–229
cancinogenesis, 100, 100(fn 15)
effects on learning, 227, 228, 229
executive functioning, 103(t), 104
state-dependent learning and, 231,
231(fn 11)
effects on memory, 231, 234–235
lung cancer, 103(tn c), 104, 107(fn 31)
psychosis, 103(t), 104(fn 20)
pulmonary toxicity, 104, 107, 107(fn 31)
factors affecting, 107
relative risk in comparison to tobacco
smoking, 107(fn 31)
Cannabis (Continued)

teratogenesis, 104, 173
   individuals with greatest risk for, 104–105
use
   by adolescents, 99–100
   during pregnancy, 104, 107, 173
   of Native descent, 173
by children, 98–99, 99(fn 13)
problems associated with early initiation of
   use, 105(fn 23, 24)
   medical, 102, 102(tm)
trends, 98–100
varieties, 97
withdrawal syndrome, 108
   factors affecting severity, 108
   signs and symptoms, 108
worldwide production, 97
(see also: Hashish; Hashish Oil; Marijuana; THC)

Cannabis Abuse Screening Test (CAST),
   270–271, 271(tm)
detection of cannabis use disorders, 270
   negative predictive value, 270
   positive predictive value, 270
   recommendations, 271
reliability, 271
scoring, 270, 271(t)
sensitivity, 270
specificity, 270
validity, 270–271

Cannabis Use Disorders Identification Test
   (CUDIT), 271–272, 272(tm)
detection of cannabis use disorders, 271
   recommendations, 272
reliability, 272
scoring, 271, 272(t)
sensitivity, 271
specificity, 271
validity, 271–272

“Capital H” see Heroin

Carcinogens
   marijuana smoke and, 100(fn 15), 101,
   103(tm c), 104, 107(fn 31)
   smokeless tobacco and, 80
   tobacco smoke and, vii(fn 9), 79
Carisoprodol
   excretion in breast milk, 206(tm)
   (see also Meprobamate)
   “Cartwheels” see Amphetamines
CAST see Cannabis Abuse Screening Test
   “Cat” see Cathinone
   (see also: Ketamine; Methcathinone)
Cathinone, 44(tm)
   (see also Psychostimulants)
   “2-CB” see 4-Bromo-2,5-dimethoxyphenethylamine
Cesamet® see Nabilone
Chantix® see Varenicline
   “Charley” see Heroin
   “Chasing the Dragon”
   definition, 8
   secondhand smoke exposure and, 213
Chemoreceptor Trigger Zone
   opiate analgesics and, 9
Cheroots® see Tobacco Cigarillos
   “Chew” see Chewing Tobacco
   Chewing Tobacco, 81(tm)
   (see also Tobacco, Smokeless)
   “Clickems” see “Fry”
Child (Children)
   age-associated harm associated with drug and
   substance use, 320
   attraction to particular drugs and substances of
   abuse, 320
   child neglect, xii(fn 9), 200, 203
   definition of child, xiii(fn 13)
   definition of childhood, xiii(fn 13)
   lack of available quick-screen psychometric
   tests, 258(fn 13)
   protective factors from drug and substance
   use, 323
   risk factors for drug and substance use, 323
   (see also: Boys; Girls)
   “Chipping”
   definition, 8
   heroin, 8

3This is a good example of the dangers associated with using slang terms and street names. Because their
   meanings are neither formalized nor standardized and can vary from user group to user group, from geographic
   location to geographic location, and from time to time, miscommunication can easily result. In order to be
   able to fully communicate, in the context of clinical practice, with drug and substance users, familiarity with,
   and use of, these terms (i.e., the argot of the “addict”) are required. However, given the obvious “dangers”, we
   strongly suggest that clinicians verify with their patients, as we routinely do, that the names or terms used mean
   the “same thing” to both the user and the clinician.
Chloral Hydrate, 6(t)
brand/trade names, 6(t)
common street names, 6(t)
excretion in breast milk, 206(t)
use for management of the GABA withdrawal syndrome, 32
(see also Sedative-Hypnotics)
“Chlorals” see Chloral Hydrate
Chlordiazepoxide, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
teratogenesis and, 189
use for management of the alcohol withdrawal syndrome, 25, 25(fn 27, 28), 341
(see also Benzodiazepines)
Chlorinated Hydrocarbons
products containing, 32–33
(see also Volatile Solvents and Inhalants)
Chloroform, 6(t)
(see Volatile Solvents and Inhalants)
Chronobiological Control Theory, 120–121
assumptions, 120
relationship to overdose deaths, 121
use of drugs and substances of abuse as agents of control or self-medication, 120–121
“Cig” see Cigarettes
Cigarettes
advertising, 166
combined use with caffeine, 175(fn 12)
electronic cigarette, 80, 82, 82(fn 66)
historical pattern of use, 175(fn 12)
menthol-flavored, 71–72, 79
nicotine metabolism by smokers, 83, 84(fn 70)
natural history of drug use from adolescence to the mid-30s and, 129–130
theoretical framework of developmental stages in adolescent drug involvement and, 154
use
high school students, 71, 71(tn a), 84(fn 71)
purchase of cigarettes, 84(fn 72)
North American adolescents of African descent, 71–72
relative lung cancer risk, 79
North American adolescents of European descent, 70, 71(t)
(see also: Nicotine; Tobacco)
Cigarillos, 72
attraction for youth, 72
nicotine content, 72
use
adolescent boys, 72
increase, 72
(see also: Nicotine; Tobacco)
Cigars
use
adolescents of European descent, 71(t)
high school students, 71, 71(tn b)
increase, 72
(see also: Nicotine; Tobacco)
Circuit Parties
attendance by gay and bisexual youth, 30, 51(fn 16)
GHB use and, 30
methamphetamine use and, 51(fn 16)
MDMA use and, 92
(see also: Bisexual Adolescent Boys and Young Adults; Club Drugs; Gays; HIV)
Circumplex Model of Marriage and Family Therapy, 156–157
adaptability, 156, 157
family cohesion, 156, 157
flexibility, 157, 157(fn 9)
parental modeling, 157, 157(fn 10)
single–parent families and, 157
“Clo” see Clonazepam
Clonazepam, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
pharmacological management of seizure disorders, 230–231, 231(fn 10)
teratogenesis and, 189
(see also Benzodiazepines)
Clonopin® see Clonazepam
Clorazepate, 5(t)
brand/trade names, 5(t)
teratogenesis and, 189
(see also Benzodiazepines)
Clubbing
methamphetamine use and, 51(fn 16)
MDMA use and, 89
psychodelic use and, 88
(see also Club Drugs)
Club Drugs
use by gay and bisexual adolescents and young adults, 30
(see also: Alcohol; Clubbing; Cocaine; GHB; Ketamine; Methamphetamine; MDMA; Raves)
Cocaine, 44(t, tn), 61–68
adulterants, 66
base form, 61, 62–63
Cocaine (Continued)

- extraction utilizing solvents, 62(fn 34)
- melting point, 62
- smoking, 61, 62–63
  - methylecgonidine and, 63(fn 35)
  - onset of action, 63
  - pyrolysis, 63, 63(fn 35)
  - reasons to prefer smoking over other routes of administration, 63
- toxicity associated with, 65
- solubility, 62

biological theory of sensation seeking and, 122, 124

- “cocaine blues”, 68
- cocaine hydrochloride see powder form
- coca paste, 62(fn 34)
  - extraction using solvents, 62(fn 34)
- “coke burns”, 66
- combined use with oxycodone, 175(fn 12)
- compulsive use, 68
  - history of alcoholism and, 68(fn 44)
- crack cocaine see base form
- desired actions/effects, 63

ego-self theory of substance dependence and, 137

Erythoxylon coca, 62

- excretion in breast milk, 206(t)
- freebase see base form
- general pharmacology, 62–68
  - mechanism of action, 63, 64(fig)
  - three phase theory of, 63–64
natural history of drug use and, 128

- natural source, 62
- powder form, 61, 63
  - intranasal insufflation, 61, 63
    - toxicity associated with, 65
  - intraginal administration, 65(fn 37)
  - intravenous injection, 61, 63
    - toxicity associated with, 65–66
    - “coke burns”, 66

HIV infection, 66

- pulmonary inhalation
  - cocaine base and, 62–63
  - toxicity associated with, 65
  - psychological dependence, 68
psychostimulants commonly used by children and adolescents, 45(fig)

reasons for use, 63, 226

- screening for prenatal exposure, 199
- self-medication and, 137, 300, 311(t)
- teratogenesis and, 193–195, 194(t)

theory of adolescent psychological individuation and, 139, 140

toxicities, 64–68

- direct toxicities, 64–65
  - acute toxicities, 64
  - homicide, 65
  - mental disorders associated with use, 299(t)
  - chronic toxicities, 64
    - depression, 63, 63(fn 36)
    - memory impairment, 231, 235
    - neurotoxicity, 230
    - obstetrical complications, 194(t)
    - psychological dependence, 68
    - psychosis, 65, 302
    - teratogenic effects, 194–195
  - A-D/HD and, 194
    - limitations of available data/studies, 195
    - oppositional defiant disorder and, 194
emergency department admissions and, 66
indirect toxicities, 65–66

- adulterants and, 66
  - levamisole, 66, 66(fn 39)
- intranasal insufflation and, 65
  - nasal erosion/perforation, 65
  - intravenous injection and, 65–66
    - “coke burns”, 66
    - smoking and, 65
    - “crack lung”, 65
potentially fatal toxicities

- cardiotoxicity, 66, 67, 67(fn 40)
- acidemia and, 67
- neurological damage and, 67(fn 42)
- sudden cardiac death, 67
- central nervous system hemorrhage (stroke), 66, 67, 67(fn 41)
- hyperpyrexia, 66, 67
- seizures, 66, 67

usage by North American adolescents, 61–62

Canadians, 62
- club-going adolescents, 62
  - during pregnancy, 193–194
    - of African descent, 193
    - high school students, 62
    - of Hispanic descent, 62
    - of Native descent, 173
- use with other drugs and substances of abuse, 62, 62(fn 33)
withdrawal syndrome management, 342
Codeine, viii, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
lethal dose, 215
screening for prenatal exposure, 199
(see also Opiate Analgesics)
Codeine Contin® see Codeine
“Codies” see Codeine
Coffee
cafestol, 57(fn 25)
caffeine content in coffee beans, 53(fn 19)
caffeine content in coffee beverages, 54(t)
consumption
increasing cholesterol levels and, 57(fn 25)
type 2 diabetes mellitus and, 58(fn 26)
kahweol, 57(fn 25)
natural sources, 53
(see also Caffeine)
“Coffin Nails” see Cigarettes
“Coffins” see Alprazolam
Cognitive-Behavioral Theory of Adolescent Chemical Dependency, 148–150
Alcoholics Anonymous and, 148, 150
application to treatment, 149–150
co-dependency and, 150
hypotheses, 149
plateaus of recovery, 150
Cognitive Impairment
alcohol use and, 18, 227, 227(fn 5), 228, 230,
231, 231(fn 11)
opiate analgesic use and, 11(t)
psychostimulant use and, 239(fig)
(see also: Learning; Memory; Neurotoxicity)
Cognitive Processing see Learning
Cognitive Therapy, 349
combination therapy, 349(fn 36)
efficacy, 349
intrapersonal and interpersonal components, 349(t)
(see also Psychotherapy/Counseling)
“Coke” see Cocaine
College Students
alcohol
binge drinking, 17, 17(fn 19, 20)
correlates of underage drinking, 22(fn 25)
drinking and driving, 22
factors associated with excessive alcohol use,
22, 22(fn 25)
likelihood of problematic drinking, 20(fn 23)
related academic problems, 20
related injury and death, 20
use of energy drinks and, 17
family interactional theory of adolescent drug use and, 163
MDMA
use by bisexual, gay, and lesbian college students, 92
Combined Drug Use see Poly Drug Use
Comorbidity see Dual Diagnosis
Compulsive Use
physical dependence and, 61(fn 29)
(see also Patterns of Drug and Substance Use)
Concealment of Drug and Substance Use, 245,
246(t, tn a), 256–258, 256(fn 11),
257(fn 12)
North American adolescents of African descent, 245
(see also Detecting Adolescent Use of the Drugs and Substances of Abuse)
Concerta® see Methylphenidate
Conocybe Mushrooms, 94
Controlled Use see Patterns of Drug and Substance Use
Copenhagen® see Tobacco, Smokeless, Chewing
Copenhagen Straight® see Tobacco, Smokeless, Dipping
“Co-Pilot” see Amphetamine
Correction Fluid see Chlorinated Hydrocarbons commonly abused volatile solvents and inhalants, 34
(see also Volatile Solvents and Inhalants)
“Cotton” see Oxycodone
“Cough Syrup” see Codeine
Counseling see Psychotherapy/Counseling
“Crack” see Cocaine
CRAFFT, 272–273, 273(t)
detection of AUDs, 272
detection of SUDs, 272
negative predictive value, 273
North American adolescents of Native descent, 273
positive predictive value, 273
reliability, 273
CRAFFT (Continued)
score, 273, 273(t)
sensitivity, 273
specificity, 272
validity, 273
“Crank,” see Methamphetamine

Craving
alcohol use and, 22
among girls, 84
disruptive environment theory and, 135, 136
methamphetamine use and, 167
(see also Psychological Dependence)

Criminal Gangs
involvement in heroin trade, 7(fn 5), 8, 8(fn 8)
involvement in methamphetamine production
and commerce, 46, 46(fn 5)
involvement in phencyclidine production and
commerce, 109
North American adolescents of Hispanic
descent, heroin use and, 7(fn 5)
youth gang activity, 117
(see also Juvenile Justice System)

Criminology and Deviance Theories of Drug and
Substance Use, 151–155

“Crystal Meth,” see Methamphetamine

CUDIT see Cannabis Use Disorders Identification Test

Curiosity
as a reason for drug use, 123

Cylert® see Pemoline

D
Dalmane® see Flurazepam
Dance Clubs see Clubbing
“Dancing Shoes” see MDMA
D.A.R.E. see Drug Abuse Resistance Education
Darvon® see Propoxyphene
Darvon-N® see Propoxyphene
DAST see Drug Abuse Screening Test

Date Rape see Sexual Assault
“Death,” see Paramethoxyamphetamine
(see also following entry)

Death
alcohol use and, 13(fn 15), 18(fn 21), 20
butane use and, 38, 39
chronobiological control theory and, 121
codeine use and, 215
incomplete mourning theory and, 155, 156
initiatory model of drug abuse and, 144, 145
LSD use and, 95
MDMA use and, 93–94
North American adolescents of African descent,
leading cause, 118
North American adolescents of European
descent, leading cause, 118
PCP use and, 113–114
solvent use and, 39–40, 39(fn 45), 40(fn 46)
tobacco use and, 78, 78(fn 63), 79
(see also: Homicide; Median Lethal Dose;
Overdosage; Suicide; Unintentional
Childhood Poisonings)

Definitions
abusable psychotropic, vii (fig 1)
“airblasting”, 35
“AMP”, 110
“bagging”, 35
“balling”, 65(fn 37)
“Belushi”, 62(fn 33)
bidis, 73
binge drinking, 15
“blunts”, 98(fn 11)
“bong”, 101
caffeinism, 59
cannabinoids, 100
“chasing the dragon”, 8
chem”, 81
dipping”, 8
dipping”, 8
“chillim”, 102
cisco”, 110
clickems”, 110
cocaine blues”, 68
coke burns”, 66
delirium tremens, 24
dip”, 81(t)
dobie”, 98
dual diagnosis, 289
embalming fluid, 110(fn 34)
erogenic effects, 58
endocannabinoid system, 100
“flamethrower”, 62(fn 33)
frios”, 110
“Frisco special”, 62(fn 33)
“Frisco speedball”, 62(fn 33)
fry”, 110
galyan”, 102
gasing”, 35
glading”, 35
“H & C”, 62(fn 33)
hallucination, 229(fn 9)
hashish, 98
hashish oil, 98
“hookah”, 101, 102
“huffing”, 35
illusion, 229(fn 9)
illy”, 110
“joint”, 98, 101
kif, 98(fn 10)
kreteks, 73
“meth mouth”, 50(fn 14)
“murder one”, 62(fn 33)
“narc”, 51
“nargile”, 102
nonabusable psychotropic, vii (fign 1)
oiling”, 35
“painting”, 35
“penny cleaning”, 35
psychedelic, 87
psychotropic, vii (fign 1)
rave, 89(fn 4)
“reefer”, 98, 101
“run”, 50
“rush”, 8(fn 11)
sacking”, 35
“Sherm stick”, 110
“shisha”, 102
Sinsemilla, 97
“sniffing”, 35
“snorting”, 4
“speedball”, 62(fn 33)
“spraying”, 35
“super labs”, 46(fn 5)
“Texas shoe-shining”, 35
volatile solvent, 32
“wet”, 110
“Delaud” see Hydromorphone
Delinquent Behavior
deviance theory: an explanatory model and,
154–155
dual diagnosis
SUD and ODD and, 294
(see also: Criminal Gangs; Incarcerated Youth;
Juvenile Justice System)
Delirium Tremens
definition, 24
management, 25(fn 28)
signs and symptoms, 24–25
(see also: Alcohol; Alcoholism)
Demerol® see Meperidine
“Dems” see Meperidine
Dependence
disruptive environment theory and, 135, 136
(see also: Physical Dependence; Psychological
Dependence)
Depression
alcohol use and, 12
cocaine use and, 63, 63(fn 36)
dependence on cocaine and, 137
effects on memory, 242
ego-self theory of substance dependence and, 137
LSD use and, 95
self-medication and, 69, 137, 138
tobacco smoking and, 69
(see also: Dual Diagnosis; Psychodepressants)
“Desert Tea” see Ephedrine
Designated Driver Program, 324
Desoxyn® see Methamphetamine
“DET” see N,N-Diethyltryptamine
Detecting Adolescent Use of the Drugs and
Substances of Abuse, 245–288
accurate diagnosis, 248–250
concealment of use, 245, 246(tn a), 256–258,
256(fn 11), 257(fn 12)
North American adolescents of African
descent, 245
flowchart, 247(fig)
missed diagnoses, 246(t)
(see also Quick-Screen Psychometric Tests)
Deviance Theory: An Explanatory Model, 154–155
assumptions, 155
delinquent behavior and, 154–155
“Dex” see Detroamphetamine
Dexedrine® see Dextroamphetamine
“Dexies” see Detroamphetamine
Dextroamphetamine, 44(t)
brand/trade names, 44(t)
common street names, 44(t)
prodrug, 43(fn 1)
(see also Amphetamines)
Diagnosis see Detecting Adolescent Use of the
Drugs and Substances of Abuse
Diagnostic and Statistical Manual of Mental Disorders
criteria for A-D/HD, 238(t)
dependence, 61(fn 29), 108(fn 32)
flowchart for diagnosing SUDs and, 247(fig)
Diagnostic Errors
missed diagnoses, 246(t)
type 1 and type 2, 248–250, 251(fig)
(see also Detecting Adolescent Use of the Drugs
and Substances of Abuse)
Diazepam, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
state-dependent learning and, 231, 231(fn 11)
teratogenic risk, 189
use for management of withdrawal syndromes
alcohol withdrawal syndrome, 25, 25(fn a), 341
benzodiazepine withdrawal syndrome, 28
gamma-aminobutyric acid withdrawal
syndrome, 31–32
Diazepam (Continued)
sedative-hypnotic withdrawal syndrome, xiv
(see also Benzodiazepines)
Dicodid® see Hydrocodone
Didrex® see Benzphetamine
Diethylpropion, 44(t)
(see also Psychostimulants)
N,N-Diethyltryptamine, 90(t)
natural source, 94
(see also LSD-Like Psychodelics)
“Dip” see Dipping Tobacco
“Diet Pills” see Phendimetrazine
Dilaudid® see Hydromorphone
“Dillies” see Hydromorphone
2,5-Dimethoxy-4-methylamphetamine, 90(t)
N,N-Dimethyltryptamine, 90(t)
Dipping Tobacco, 81(t)
(see also Tobacco, Smokeless)
N,N-dipropyltryptamine, 90(t)
“DIPT” see N,N-Dipropyltryptamine
Disruptive Environment Theory, 132–136
craving and, 135–136
dependence and, 135–136
hypotheses, 133
“road to h”, 132
tolerance and, 135–136
Distilled Spirits see Alcohol
Disulfiram
adverse effects when combined with alcohol use, 343
combination therapy, 343(fn 33)
efficacy, 343(fn 33)
flush associated with use, 343
four-circuit neurobehavioral model of addiction and, 126
prevention of resumed drinking, 338, 343–344
“Diviner’s Mint” see Salvia divinorum
Djarum Black® see Kreteks
“DMT” see N,N-Dimethyltryptamine
“Dollies” see Methadone
Dolophine® see Methadone
“DOM” see 2,5-Dimethoxy-4-methylamphetamine
“Done” see Methadone
“Dons” see Nitrazepam
Don’t Drink and Drive Program, 324
“Doobie” see Marijuana Cigarette
“Drag”, 98
“Drink” see Alcohol
Drinking and Driving see Driving Under the Influence / Driving While Impaired
Driving Under the Influence / Driving While Impaired risk of motor vehicle crash and, 22, 22(fn 24), 24(fig)
alcohol use, 13, 24(fig)
cannabis use, 104, 106–107, 106–107(fn 30)
combined alcohol and cannabis use, 105, 106(fn 29)
“Drone” see Mephedrone
Drug Abuse Resistance Education (D.A.R.E.)
efficacy, 329(13), 333(fn 19), 334
use of social environmental/learning model, 327
Drug Abuse Screening Test (DAST), 273–275, 274(t)
detection of SUDs, 273
reliability, 275
scoring, 274(t), 275
sensitivity, 275
specificity, 275
validity, 275
Drug Abuse Screening Test (Revised) see Drug Abuse Screening Test
Drug Abuse Screening Tests see Quick-Screen Psychometric Tests
Drug-Facilitated Sexual Assault see Sexual Assault
Drug-Free America, 324
Drugs and Substances of Abuse, vii(fig 1)
Drug Screening
neonatal screening, 178, 182(t), 187–188, 199–200
criteria for urine testing, 182(t)
(see also Drug Abuse Screening Tests)
Drug, Set, and Setting, 160
Drugs Excreted in Human Breast Milk see Breast Milk
“Drug Store” see Morphine
Drug Subculture Theory see Theory of Drug Subculture
Drug Use Disorders Identification Test (DUDIT), 275–276, 276(t)
detecting SUDs among adolescents, 275
recommendations, 276
reliability, 276
scoring, 275, 276(t)
sensitivity, 275–276
specificity, 275–276
validity, 276
Dry Snuff, 81(t)
(see also Tobacco, Smokeless)
Dry Snus, 81(t)
(see also Tobacco, Smokeless)
DSM see Diagnostic and Statistical Manual of Mental Disorders
DTs see Delirium Tremens
Dual Addiction see Dual Diagnosis
Dual Diagnosis, 289–316
  clinical consequences of, 291
  common SUDs and OMDs involved, 290(fig)
  correlates of, 291
  definition, 289
  incidence, 290
  list of commonly involved OMDs, 292(t)
  possible relationships, 291(fig)
  self-medication, 292(fn 8), 295, 298, 300, 301, 303, 306(t), 307, 310, 311(t)
SUDs and anxiety disorders, 292(t), 294–296
  panic disorder, 294–296
  PTSD, 295–296
SUDs and mood disorders, 292(t), 296–301
  bipolar disorder, 297, 297(fn 14)
  major depressive disorder, 297–298, 300–301
  alcohol and, 297–298, 298(fn 15)
  suicide, 300
  cannabis and, 300
  cocaine and, 300
  nicotine and, 300–301
SUDs and OMDs usually first diagnosed in infancy, childhood, or adolescence, 292–294, 292(t)
A-D/HD, 292–293, 292(fn 8)
  conduct disorder, 293–294
  oppositional defiant disorder, 294
SUDs and personality disorders, 292(t), 301–302
  antisocial personality / conduct disorder, 301
  borderline personality disorder, 301–302
SUDs and psychotic disorders, 292(t), 302–304
  schizophrenia, 302–304
  cannabis and, 303–304, 303(fn 18)
SUDs and sexual or gender identity disorders, 292(t), 304–305, 306(t)
SUDs and sleep disorders, 292(t), 305–307
  insomnia, 306–307
  treatment, 309–315, 348, 348(fn 35)
  approaches, 310–315
  developmental biopsychosocial disease model, 312
dual disorders recovery counseling, 312–313
  family-based therapies, 313–314
  holistic model of treatment, 313
  individualized approaches, 314–315
  pharmacotherapy, 348
  psychotherapy, 348(fn 35)
  barriers, 309–310
  consequences of non-treatment, 291
  therapeutic guidelines, 315, 315(t)
(see also Tridiagnosis)
Energy Drinks, 54–55(t), 55(tn, d, e), 56–57
  alcohol use and, 57
  caffeine content, 54–55(t)
  definition, 17
  effects on alcohol intoxication, 17–18
  effects on self-perception of alcohol intoxication, 18
  problem behavior related to use, 17
  reasons for use, 18, 57
  use by adolescents, 56–57
  use by college students, 17
  (see also Caffeine)
Entactogens see Psychodelics
Environmental Smoke Exposure see Secondhand Smoke
Ephedra, 48
  (see also Ephedrine)
“Ephedrine” see Methcathinone
  (see also following entry)
Ephedrine, 44(t, tn)
  nutritional supplements and, 55(tn)
  relationship to amphetamines, 46(fn 5), 47–48
  source countries, 46(fn 5)
  use in the production of methamphetamine, 46(fn 5)
  (see also Psychostimulants)
Epilepsy see Seizure Disorders
Equanil® see Meprobamate
Ergogenic Effects
  caffeine and, 57–58
  definition, 58
  nutritional supplements and, 55(tn)
Estazolam, 6(t)
  brand/trade names, 6(t)
  teratogenesis and, 189
  (see also Benzodiazepines)
Eszopiclone
  brand/trade names, 6(t)
  (see also Z-Drugs)
“ET” see Alpha-ethyltryptamine
Ethanol see Alcohol
Ether, 6(t)
  (see Volatile Solvents and Inhalants)
Ethical/Legal Issues, 175(fn 11), 200
Ethnic-Specific Treatment Programs, 356–357
  paucity of data, 357
  (see also Psychotherapy/Counseling)
Ethyl Alcohol see Alcohol
“Eve” see 3,4-Methylenedioxymethamphetamine
Executive Functioning see Learning
Existential Theory of Drug Dependence, 136–137
  application to treatment, 136–137
  hypotheses, 136
  self-medication and, 136
Explaining Use of the Drugs and Substances of Abuse see Theories of Adolescent Drug and Substance Use
Exposure to the Drugs and Substances of Abuse, 171–219
  exposure during breast-feeding, 200–203, 204–210(t)
  exposure during pregnancy, 172–200
  exposure to secondhand smoke, 203, 203(fn 27), 211–213
  exposure by unintentional childhood poisonings, 213–218
F
Fagerstrom Test for Nicotine Dependence (FTND), 276–277
  detecting nicotine use disorders among adolescents, 277
  negative predictive value, 277–278
  positive predictive value, 277–278
  recommendations, 278
  reliability, 278
  scoring, 277, 277(t)
  sensitivity, 277–278
  specificity, 277–278
  validity, 278
Family
  cohesion
    circumplex model of marriage and family therapy and, 156, 157
    family interactional theory of adolescent drug use, 163
  family systems theories of drug and substance use, 155–158
  types, 222(fn 1)
  violence, xii(fn 9)
  (see also: Family Therapy; Parents)
Family Therapy, 350–354, 350(fn 38), 352(t)
  behavioral family therapy, 351–352
    contingency/behavioral contracting, 351–352
    training component, 353
  general guidelines, 351(t)
  goals, 350
  issues, 352
  multidimensional family therapy, 354
  juvenile offenders and, 354
  multisystemic therapy, 354
  strategic-structural family therapy, 353–354
  optimal communication technique, 354
reframing, 353
restructure, 353
validation, 354
types, 352(t)
use with adolescent mothers who use drugs and substances of abuse, 350(fn 38)
use with children and adolescents with A-D/HD, 350(fn 38)
(see also: Family; Psychotherapy/Counseling)
FAS see Fetal Alcohol Syndrome / Fetal Alcohol Spectrum Disorder
FASD see Fetal Alcohol Syndrome / Fetal Alcohol Spectrum Disorder
Fastin® see Phentermine
Fathers see Parents
FDA see Food and Drug Administration
Females see Girls
“Fen” see Fentanyl
Fentanyl, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
unintentional childhood poisonings, 215
use by children and adolescents, 4(fn 3)
(see also Opiate Analgesics)
Fetal Alcohol Effects, 185–186
(see also FAS / FASD)
Fetal Alcohol Syndrome / Fetal Alcohol Spectrum Disorder (FAS / FASD), ix, 18, 20, 179, 183–188, 241–242
A-D/HD and, 187
characteristics, 183–184, 184(t), 185(fig)
cognitive-processing-related learning deficits, 241
conduct disorder and, 187
craniofacial characteristics, 185(fig)
diagnostic criteria, 183–184, 184(t), 185(fig)
diagnostic code, 186(t)
fatty acid ethyl esters and, 187–188
history, 183, 183(fn 14)
incidence, 20, 184–185, 184(fn 15), 187(t)
North American adolescents of Native descent, 184, 187(t)
long-term sequelae, 187
learning problems, 241–242
mechanism, 20
mental retardation and, 18, 20, 241, 241–242 (fn 21)
Native Americans and, 20, 241(fn 22)
prevalence of associated abnormalities, 184(t)
screening, 187–188
treatment recommendations, 188, 188(fn 17)
(see also: Alcohol; Dual Diagnosis)
“Fido-Dido” see N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine
Film Strips, 81(t)
(see also Tobacco, Smokeless, Dissolvable)
Fiorinal®, 6(tn f)
“Flake” see Cocaine
“Flamethrower”, 62(fn 33)
Flashbacks, 96, 96(fn 6, 7)
olfactory memory and, 96(fn 6)
(see also LSD)
“Flatliners” see 4-Methylthioamphetamine
“Flesh of the gods” see Amanita muscaria
Flumazenil
GABA receptor complex and, 23(fig)
treatment of benzodiazepine overdosage, 29, 338, 340, 341
reversal of benzodiazepine memory impairment, 233
Flunitrazepam, 6(t)
brand/trade names, 6(t)
combined use with other drugs and substances of abuse, 26(fn 30)
common street names, 6(t)
Mexico as a primary source country, 26(fn 30)
sexual assault and, 6(tn g), 26, 26(fn 30)
teratogenesis and, 189
use by adolescent girls, 26(fn 30)
use by North American adolescent boys of European descent, 26(fn 30)
use by North American adolescent boys of Hispanic descent, 26(fn 30)
(see also Benzodiazepines)
Fluorinated Hydrocarbons
products containing, 32
(see also Volatile Solvents and Inhalants)
Flurazepam, 6(t)
brand/trade names, 6(t)
teratogenesis and, 189
(see also Benzodiazepines)
“Fly” see Piperazine Derivatives
Fly Agaric see Amanita muscaria
Food and Drug Administration
pregnancy codes, 174(t), 174(fn 8)
regulations to reduce tobacco use by children and adolescents, 74–75
bans on cigarette flavoring, 74
cigarette package warning labels, 74–75
restriction of the distribution, sale, and marketing of cigarettes and smokeless tobacco to children and adolescents, 74, 75(t)
“Footballs” see Alprazolam
  (see also: Propoxyphene; index fn 3)
“Forget-Me Drug” see Flunitrazepam
“Forget-Me Pill” see Flunitrazepam
Formaldehyde
  combined with phencyclidine, 110
  use by North American adolescents of Hispanic
descent, 110
  (see also: “Fry”; Phencyclidine)
Four-Circuit Neurobehavioral Model of Addiction
  application to treatment, 126–127
  assumptions, 124–125
  hypotheses, 125
Four-Factor Model of Adolescent Drug
  Involvement, 150–151
“Foxy” see 5-Methoxy-N,N-diisopropyltryptamine
“Foxy Methoxy” see 5-Methoxy-N,N-diisopropyl-
tryptamine
Freons see Fluorinated Hydrocarbons
  use by air conditioning repair technicians, 34(fn
39)
  (see also Volatile Solvents and Inhalants)
“Frios” see “Fry”
“Frisco Special”, 62(fn 33)
“Frisco Speedball”, 62(fn 33)
“Fry”
  definition, 110
  embalming fluid, 110, 110(fn 34)
  formaldehyde, 110
  method of use, 110
  use with fortified wine, 110
  toxicity
    management, 110
    signs and symptoms, 110
  (see also Phencyclidine)
FTND see Fagerstrom Test for Nicotine
  Dependence
“Fungus” see Psilocybin

G
GABA see Gamma-Aminobutyric Acid
Gamma-Aminobutyric Acid (GABA)
  receptor complex, 23(fig)
  relationship to GHB, 30
Gamma-Butyrolactone, 29
  conversion to GHB, 29(fn 33)
  (see also GHB)
Gamma-Hydroxybutyrate (GHB), 29-32
  alcohol-like disinhibitory euphoria, 29
  anterograde amnesia and, 30, 31, 231, 235
  brand/trade name, 6(t)
circuit party use, 30
  club drugs, 30
  combination use, 29, 30, 32
  common street names, 6(t)
  date rape and, 30–31
  enhancement of sexual experience, 30
  gamma-butyrolactone, 29, 29(fn 33)
  general pharmacology, 30–32
  Hillory J. Farias and Samantha Reid Date-Rape
    Drug Prohibition Act, 29
  mechanism of action, 31
  overdose, 32
  involvement of other drugs and substances of
  abuse, 32
  raves and, 30
  reasons for use, 29–30
  relationship to GABA, 30
  sexual assault and, 30–31
  taste, 30(fn 34)
  therapeutic use, 29, 30
  toxicity, 31
    acute, 31
    chronic, 31
    memory impairment, 30, 31, 231, 235
    typical user, 30
  use by adolescents, 30
  bisexual and gay, 29, 30
  use for self-management of the alcohol
    withdrawal syndrome, 29
  use for self-management of the opiate analgesic
    withdrawal syndrome, 29
  use for symptomatic management of narcolepsy,
    29
  withdrawal syndrome, 31–32
    management, 31–32
    signs and symptoms, 31
  Xyrem® success program, 30
  (see also Sedative-Hypnotics)
Gangs see Criminal Gangs
“Ganja” see Cannabis
“Gas” see Butane
  (see also: Gasoline; index fn 3)
“Gasing”
  definition, 35
Gasoline, 6(t), 32, 34
  burns, viii
  classification, viii(t)
  common street names, 6(t)
  commonly abused volatile solvents and
  inhalants, 34
  use to extract crude coca paste, 62(fn 34)
(see also Volatile Solvents and Inhalants)

**Gateway Hypothesis** see Theoretical Framework of Developmental Stages in Adolescent Drug Involvement

**Gays**
- attendance at circuit parties, 30, 92
- gay-oriented treatment programs, 357, 357(fn 45)
- paucity of data, 357
- GHB use, 29, 30
- methamphetamine use, 45, 46(fn 7)
- increased risk for related neurotoxicity, 48(fn 10)
- MDMA use, 91, 92
- smokeless tobacco use, 70(fn 48)
(see also: Bisexual Adolescent Boys and Young Adults; Circuit Parties; Club Drugs; HIV)

**“Georgia Home Boy”** see GHB

**Gender Effects**
- binge drinking, 15–17
- volatile solvent and inhalant poisoning, 38
(see also: Boys; Girls)

**General** see Tobacco, Smokeless, Scandinavian Snuff

**Genesis of Male Alcoholism**
- hypotheses, 127
(see also Natural History Theories of Drug and Substance Use)

**Halcion** see Triazolam

**H & C**, 62(fn 33)

**Habitual Use**
- psychological dependence and, 61(fn 29)
(see also Patterns of Drug and Substance Use)

**Habituation** see Psychological Dependence

**Halcion** see Triazolam

**“Halcyon”** see Triazolam

**“Halcyon Daze”** see Triazolam

**Harm Reduction**, 318(fig), 320, 324, 324(fn 5, 6)
- methadone maintenance, 346–347
- needle exchange programs, 320, 337, 337(fn 26)
- nicotine replacement, 346, 347–348
- safe injection sites, 337, 337(fn 26)

**Harmala Alkaloids**, 90(t)
- natural source, 94
(see also LSD-Like Psychodelics)

**Hashish**
- definition, 98
- fudge, 101
(see also: Cannabis; Hashish Oil; Marijuana; THC)

**Hashish Oil**
- definition, 98
- extraction with organic solvents, 98
(see also: Cannabis; Hashish; Marijuana; THC)

**Hawaii**
- domestic production of cannabis, 97, 98
- legal use of medical marijuana, 102(tn)
- natives at increased risk for methamphetamine-related heart failure, 50(fn 15)
- North American origin of methamphetamine epidemic, 45

**“Hawaiian Buds”** see Cannabis

**Hell’s Angels Motorcycle Gang** see Criminal Gangs

**Hepatitis (Infection)**
- associated with intravenous use, 9, 12(t)
Heroin, viii, 5(t)
age at first use, 7
“chipping”, 8
chronobiological control theory and, 121
common street names, 5(t)
criminal gang involvement, 7(fn 5), 8, 8(fn 8)
gego-self theory of substance dependence and, 137
GHB overdosage and, 32
intranasal instillation by adolescents, 8(fn 10)
intranasal insufflation by adolescents, 8
intravenous use by adolescents, 7(fn 6), 8, 8(fn 9)
natural history of drug use and, 128
purity, 8(fn 7)
“rush”, 8(fn 11)
self-medication and, 137
social use, 8
somatosensory affectional deprivation theory and, 122
source countries, 7
street level concentration, 8(fn 7)
teratogenic risk, 190
theoretical framework of developmental stages in adolescent drug involvement and, 154
theory of drug subculture and, 152
use by adolescents, 7
withdrawal syndrome management, 342(fn 30)
(see also: Black Tar Heroin; Opiate Analgesics)
Here’s Looking at You, 329
High School Students
alcohol use, 14–15
binge drinking, 16
benzodiazepine use, 26
ease of obtaining opiate analgesics, 7(fn 4)
heroin use, 7(fn 6)
intravenous drug administration, 12(tn)
LSD use, 94–95
MDMA use, 91
prescription opiate analgesic use, 7, 7(fn 4)
tobacco use, 71(t)
volatile solvent and inhalant use, 33
(see also: Adolescent; North American Adolescents)
“Hillybilly Crack” see Methamphetamine
“Hillbilly Heroin” see Hydromorphone
“Hippie Crack” see Nitrous Oxide
Hispanics
preteen marijuana use, 99(fn 13)
(see also North American Adolescents of Hispanic Descent)
HIV see Human Immunodeficiency Virus
“Hog” see Phencyclidine
Homeless Children and Adolescents
dual diagnosis and, 291
high risk of drug and substance abuse, 3
recommendation for psychometric screening, 248
use of heroin, 7
use of ketamine, 109(fn 33)
use of MDMA, 91
Wernicke-Korsakoff syndrome and, 232, 232(fn 12)
(see also Runaway Youth)
Homicide
alcohol use and, 13, 22(t)
amphetamine use and, 52, 65
cocaine use and, 65
PCP use and, 113–114
(see also Physical Assault)
Hopelessness
ego-self theory of substance dependence and, 138
“Horse” see Heroin
“Hospital Heroin” see Morphine
“Huffing”
definition, 35
Human Immunodeficiency Virus (HIV), Infection
accidental needle-stick injuries and, 212
augmentation of methamphetamine-related neurotoxicity, 48(fn 10)
bisexual adolescent boys and young men and, 291
breast-feeding and, 201(fn 26), 202(fig)
club drug use and, 308
dual diagnosis and, 291
gays and, 291
homeless youth and, 291
intravenous administration and, 9, 12(t), 66, 201(fn 26), 202(fig)
intravenous cocaine injection and, 66
lines of transmission, 202(fig)
MDMA use at circuit parties and, 92
methamphetamine use by gays and bisexuals and, 51(fn 16)
pregnancy and, 175, 202(fig)
risks associated with drug and substance abuse, 307–308
tridagnosis and, 291, 307–309, 308(fig)
(see also: AIDS)
Hycodan® see Hydrocodone
Hydrocodone, 5(t)
brand/trade names, 5(t)
combination product, 6(tn d)
common street names, 5(t)
excretion in breast milk, 208(t)
lethal dose, 215
unintentional childhood poisonings, 215
(see also Opiate Analgesics)
Hydromorphone, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
unintentional childhood poisonings, 215
(see also Opiate Analgesics)
5-Hydroxy-N,N-dimethyltryptamine, 90(t)
“Hyke” see Hydrocodone
Hyperpyrexia/Hyperthermia
amphetamine use and, 53
cocaine use and, 66, 67
definition, 67
MDMA use and, 93
Hypodermic Needle and Syringe see Intravenous Administration

I
Iatrogenic, 160, 161(fn 15)
“Iboga” see Ibogaine
Ibogaine, 44(t), 90(t, tn g)
ICD see International Classification of Diseases
“Ice” see Methamphetamine
Illusinogens see Psychodelics
“Illy” see “Fry”
Imovane® see Zopiclone
Incarcerated Youth
source of data bias, 3
use of AA with, 359
use of multisystemic therapy with, 354
use of social skills training with, 354
volatile solvent and inhalant use, 34
(see also: Delinquent Behavior; Juvenile Justice System)
Incomplete Mourning Theory, 155–156
deaths and, 155
religiosity and, 156
suicide and, 156
India
production of ephedrine and pseudoephedrine, 46(fn 5)
source country for bidis, 73
“Indian Hash” see Hashish
(see also Cannabis)
Indians see Native Americans
Indonesia
integrative family therapy model and, 163–164
source country for kretes, 73
Indonesian Cigarettes see Kretes
Initial Use see Patterns of Drug and Substance Use
Initiatory Model of Drug Abuse, 144–145
application to treatment, 145, 145(fn 7)
assumptions, 144
death and, 144, 145
hypotheses, 144–145
negative hero, 144
Integrative Family Therapy Model, 163–164
application to treatment, 164
cross-cultural testing, 163–164
Intelligence Quotient
ability to mitigate effects of drugs and substances of abuse on learning,
223, 232
binge drinking during pregnancy and, 241–242
deficits not recognized until child enters school, 221
FAS / FASD and, 241–242, 241(fn 21)
lack of academic participation in class and,
225(fn 3)
meta-variables affecting learning at the macro level, 224(fig)
Interactive Models of Nonmedical Drug Use,
160–161
self-medication and, 161
Interactive Models of Drug and Substance Abuse,
160–166
International Classification of Diseases
flowchart for diagnosing SUDs and, 247(fig)
Internet
GHB purchase, 29
purchase of precursor chemicals, 29,
29(fn 33)
kretek purchase, 73
opiate analgesic purchase, 7
purchase of drugs and substances of abuse, index
fn 2
Intranasal Administration
instillation of heroin “nose drops”, 8(fn 10)
insufflation of cocaine, 61, 63
insufflation of opiate analgesics, 4
Intravenous Administration

amphetamines, 49–50
overdosage and, 52
“run”, 50
cocaine, 61, 63
HIV infection and, 63, 66
heroin, 7(fn 6), 8, 8(fn 9)
methamphetamine and, 43(fn 2)
HIV infection and, 51(fn 16)
needle/syringe sale by adolescents with diabetes, ix
PCP, 109
sites, 12(tn)
toxicity, 12(t)
associated with adulterants, 10, 12(tn)
talc granulomas, 9, 12(tn)
associated with method of administration, 10, 12(t)
HIV infection and, 51(fn 16), 63, 201, 201(fn 26), 202(fig)
cocaine, 65–66
opiate analgesics, 9–10
use by high school students, 12(tn)
(see also Needle Exchange Programs)
Inuit
volatile solvent and inhalant abuse, 34(fn 42)
(see also: Alaskan Natives; Native Americans)
Ionamin®, see Phentermine
IQ see Intelligence Quotient
Isobutane, 39(fn 45)
(see also Nonhalogenated Hydrocarbons)
Involuntary Smoking see Secondhand Smoke
Isoquinoline Alkaloids, 4(fn 2)
“3-IT” see Alpha-methyltryptamine

J
“Jamaican Ganja” see Cannabis
“Java” see Coffee
“Jib” see Methamphetamine
“Jif” see Methylphenidate
Jimsonweed, 87(fn 1)
“Joe” see Coffee
“Joint” see Marijuana Cigarette
“Junk” see Heroin
Just Say No, 329
Juvenile Justice System
recommendation for psychometric screening of adolescents, 248
volatile solvent and inhalant use and, 34
(see also: Delinquent Behavior; Incarcerated Youth)

K
“K” see Ketamine
Kahweol, 57(fn 25)
(see also Coffee)
“Kai” see Kif
“Kat” see Cathinone
“Katovit” see Prolintane
“Keef” see Kif
Ketalar® see Ketamine
Ketamine, 90(t), 97, 109
intramuscular and intravenous use, 109(fn 33)
(see also Psychodelics)
“Khat” see Cathinone
“Kief” see Kif
Kif
definition, 98(fn 10)
source country, 98(fn 10)
(see also Cannabis)
“Kitty” see Methcathinone
“Klonnies” see Clonazepam
Kool® see Tobacco Cigarettes
Korsakoff’s Psychosis see Wernicke-Korsakoff Syndrome
Kreteks, 72–73
availability, 73
clove content, 73
nicotine content, 73
popular brand, 73(fn 53)
use by North American adolescents, 73

L
Laboratory Tests
for detection of alcoholism, 250(fn 4)
Lack of Political or Social Resolve, 331–332
tobacco use and, 332, 332(fn 17, 18)
underfunding, 331(fn 16)
(see also Primary Prevention)
“Lady” see Cocaine
“La Roche” see Flunitrazepam
“Laughing Gas” see Nitrous Oxide
LD50 see Median Lethal Dose
“LDX” see Lisdexamfetamine
Learning, 221–242
A-D/HD and, 237–241, 238(t), 239(fig)
cognitive approach toward, 222(fn 2)
cognitive input-output model, 224–226, 225(fig)
core processes, 223, 224(fig), 226–231
attention, 224(fig), 226–228
definition, 226
negative effects of drug and substance use on, 227–228
positive effects of drug and substance use on, 226–227
cognitive processing, 224(fig), 230–231
definition, 230
reduced global cerebral metabolic rate, 230–231, 231(fn 10)
state-dependent learning, 231
motivation, 224(fig), 228–229
amotivational syndrome, 228, 228(fn 7)
definition, 228
negative effects of drug and substance use on, 228–229
perception, 224(fig), 229–230, 229(fn 8, 9)
definition, 223
effects of drugs and substances of abuse, 221–242
executive functioning
amphetamine use and, 50(fn 13)
cannabis use and, 103(t), 104
meta-variables, 223, 224(fig)
parents and, 222, 224(fig)
sensory impairment and, 226(fn 3)
teachers and, 222, 223, 224(fig)
thoretical orientations, 222(fn 2)
variables affecting learning at the macro level, 223, 224(fig)
unit coterie, 224
(see also: Memory; Schools; Teachers)
Learning Theories of Drug and Substance Use, 147–150
(see also Theories of Adolescent Drug and Substance Use)
Learning to Live Drug Free, 334(fn 21)
“Lebanese Hash” see Hashish
(see also Cannabis)
“Lebuga” see Ibogaine
Lectopam® see Bromazepam
Lesbian Adolescent Girls
binge drinking and, 17
lesbian oriented treatment programs, 357, 357(fn 45)
paucity of data, 357
methamphetamine use and, 46
MDMA use and, 91, 92
smokeless tobacco use and, 70(fn 48)
tridiagnosis and, 308, 308(fig)
(see also: Adolescent Girls; Girls)
Levo-Dromoran® see Levorphanol
Levorphanol, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
(see also Opiate Analgesics)
“Libbies” see Chlordiazepoxide
“Libs” see Chlordiazepoxide
Librium® see Chlordiazepoxide
Life Process Program Theory of Natural Recovery, 147–148
application to treatment, 147–148
assumptions, 147
Life Skills Training, 329
Lighter Fluid see Butane
commonly abused volatile solvents and inhalants, 34
(see also Volatile Solvents and Inhalants)
“Lillys” see Secobarbital
Lions-Quest Skills for Adolescence, 329
“Liquid Courage” see Alcohol
Liquid Paper® see Chlorinated Hydrocarbons
Liquor see Alcohol
Lisdexamfetamine, 44(t)
brand/trade name, 44(t)
common street name, 44(t)
inactive prodrug, 43(fn 1)
(see also Amphetamines)
“Living on the Streets” see Homeless Children and Adolescents
(see also Runaway Youth)
Long-Term Memory see Memory
Lorazepam, 6(t)
benzodiazepine withdrawal syndrome and, 28
brand/trade names, 6(t)
common street names, 6(t)
teratogenesis and, 189
use for management of the GABA withdrawal syndrome, 31–32
(see also Benzodiazepines)
Lortab®, 6(tnd)
Loss of Control and Compulsive Drug Use see Four-Circuit Neurobehavioral Model of Addiction
“Love Drug” see 3,4-Methylenedioxymethamphetamine
(see also: MDMA; index fn 3)
“Love Pearls” see Alpha-ethyltryptamine
“Lozenges”, 82(t)
(see also Tobacco, Smokeless, Dissolvable)
LSA see Lysergic Acid Amide
LSD see Lysergic Acid Diethylamide
Luminal® see Phenobarbital
Lunata® see Zopiclone
Lunesta® see Eszopiclone
Lung Cancer
cannabis smoking and, 100(fn 15), 101, 103(tnc), 104, 107(fn 31)
tobacco smoking and, xii(fn 9), 79
“Lung Darts” see Cigarettes
Lysergic Acid Amide, 90(t)
natural source, 94
(see also LSD-Like Psychodelics)
Lysergic Acid Diethylamide (LSD), 90(t), 94–97
*biological theory of sensation seeking* and, 122, 123
combined use with MDMA, 175(fn 12)
derivation from ergot alkaloid, 95
general pharmacology, 95–97
mechanism of action, 95
median lethal dose, 95
potency, 88(fn 2)
synthesis, 95
teratogenesis and, 95, 173, 199
*theoretical framework of developmental stages in adolescent drug involvement* and, 154
*theory of object relations and adolescent compulsive drug use* and, 142
tolerance, 96–97
cross-tolerance, 97
reverse tolerance, 97
toxicities
physical, 95
neurotoxicity, 230
teratogenesis and, 95, 173, 199
psychological, 95–96
anxiety disorders, 96
flashbacks, 96, 96(fn 6, 7)
management, 96
hallucinogen-persisting perception disorder, 96
management, 96
mood disorders, 96
suicide and, 96
psychotic disorders, 96
management, 96
related deaths, 95
use by adolescents, 94–95
use by high school students, 94–95
(see also Psychodelics)
Lysergic Acid Diethylamide-Like Psychodelics, 94–97
(see also Psychodelics)

**M**
MADD see Mothers Against Drunk Driving
“Magic” see Nutmeg
“Magic Mushrooms” see Psilocin

“Mainlining” see Intravenous Administration
Major Depressive Disorder see Depression
Males see Boys
Marijuana
*biological theory of sensation seeking* and, 122, 123
Canadian marijuana, 98, 98(fn 9)
domestic production, 97–98
ease of obtaining by adolescents, 99
*family interactional theory of adolescent drug use* and, 163
“grow op”, ix
definition, 98(fn 9)
secondhand smoke exposure and, 211
high potency, 98, 98(fn 9, 12)
importation, 98, 98(fn 9)
legalization, 99–100, 100(fn 14)
medical marijuana, 100(fn 14), 101, 102(t)
indications for use, 102(t, tn a)
states with programs, 102(tn)
methods of use, 101–102
edible products, 101
marijuana beer, 101(fn 17)
pulmonary inhalation, 101
smoking, 101–102
cigarette, 98
vaporization, 101–102
*natural history of drug use from adolescence to the mid-30s* and, 129–130
*predictive model of adolescent use of the drugs and substances of abuse* and, 150
*problem behavior theory: a field theory of problem drinking* and, 161
THC concentration, 98, 98(fn 12)
*theoretical framework of developmental stages in adolescent drug involvement* and, 154
*theory of drug subculture* and, 152–153
use
by adolescents, 98–100
adolescents of African descent, 99
during the Prohibition Era, 117
by children of Hispanic descent, 99(fn 13)
by high school students, 99–100
factors supporting, 100
favorable attitudes toward, 100, 100(fn 14)
medical use, 101, 102(t, tn)
*somatosensory affectional deprivation theory* and, 122
(see also: Cannabis; Hashish; Hashish Oil; THC)
Marinol® see Dronabinol
Marlboro Snus® see Tobacco, Smokeless, American Snuff
MAST see Michigan Alcoholism Screening Test
Maturing-Out Theory, 158(fn 11)
Mazindol, 44(t)
(see also Psychostimulants)
“MBDB” see N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine
“MCAT” see Mephedrone
McChrystal’s Apricot Snuff® see Tobacco, Smokeless, Snuff
MDA see Methyleneoxyamphetamine
MDE see 3,4-Methylenedioxyethylamphetamine
MDEA see 3,4-Methylenedioxyethylamphetamine
MDMA see Methyleneoxymethamphetamine
Mebaral® see Mephobarbital
Meconium
definition, 199(fn 24)
use in identifying fetal drug exposure, 199(fn 24), 199–200
Median Lethal Dose
definition, 29
for amphetamines, 53
for benzodiazepines, 29
for LSD, 95
Medical Marijuana see Marijuana
Memory, 224(fig), 225(fig), 231–236
alcoholic blackout see anterograde amnesia
anterograde amnesia
alcohol use and, 23, 232
benzodiazepine use and, 233
reversal by benzodiazepine antagonist, 233
therapeutic application, 233(fn 14)
GHB use and, 30, 31, 235
PCP use and, 111–112, 111(fn 35)
cognitive input-output model, 224–226, 225(fig)
effects of depression, 242
effects of drugs and substances of abuse, 221–242
encoding process, 225–226, 230, 235
cannabis use and, 234
engrams and, 225(fig), 226
FAS / FASD and, 241
GHB use and, 235
psychodelic use and, 229
rehearsal strategies and, 225–226
visual cues and, 226
episodic memory
alcohol use and, 232
GHB use and, 235
MDMA use and, 236
explicit memory
benzodiazepine use and, 233
long-term memory, 225(fig)
cannabis use and, 234
functional storage capacity, 226
MDMA use and, 236
types of information stored, 226
olfactory memory
LSD use and, 96(fn 6)
prospective memory
alcohol use and, 232
definition, 232–233
residual memory
cocaine use and, 235
confounding variables, 235
retrograde amnesia
alcohol use and, 232
Wernicke-Korsakoff syndrome and, 232
sensory impairment and, 225(fn 3)
short-term memory, 225(fig)
FAS / FASD and, 241
cannabis use and, 234
duration of storage, 225
functional storage capacity, 225
MDMA use and, 236
spatial working memory
alcohol use and, 232
MDMA use and, 236
verbal memory
FAS / FASD and, 241
benzodiazepine use and, 233
methamphetamine use and, 235–236
MDMA use and, 93, 93(fn 5)
visual memory
benzodiazepine use and, 233
working memory, 225(fig)
FAS / FASD and, 241
GHB use and, 235
MDMA use and, 236
(see also Learning)
Mental Depression see Depression
Mental Retardation
administration of quick-screen psychometric tests and, 256
dual diagnosis and, 292(fn 7)
FAS / FASD and, 18, 20, 241–242, 241(fn 21)
Mental Retardation (Continued)
(see also: Intelligence Quotient; Learning; Neurotoxicity)
“5-MeO-DMT” see 5-Methoxy-N,N-dimethyltryptamine
“5-MeO-DIPT” see 5-Methoxy-N,N-diisopropyltryptamine
“Meow” see Mephedrone
“Mep” see Meperidine
(see also: Meprobamate; index fn 3)
Meperidine, viii, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
overdose
   signs and symptoms, 14(t)
teratogenesis and, 190
(see also Opiate Analgesics)
“Meph” see Mephedrone
Mephedrone, 44(t)
(see also Psychostimulants)
Mephentermine, 44(t)
(see also Amphetamines)
Mepobarbital
teratogenesis and, 188–189
(see also Barbiturates)
Meprobamate
excretion in breast milk, 207(t)
teratogenesis and, 189–190
(see also Carisoprodol; Sedative-Hypnotics)
Meridia® see Sibutramine
“Mescalamphetamine” see 3,4,5-
   Trimethoxyamphetamine
Mescaline, 90(t)
classification, viii(t)
cross-tolerance, 97
potency, 88(fn 2)
(see also Psychodelics)
Meta-Interactive Model of Child and Adolescent
   Use of the Drugs and Substances of Abuse, 322, 338(fn 27), 361–362
description, xiv, 322(fig)
dimensions, 322(fig), 361
use to evaluate relapse prevention, 362
use to evaluate treatment, 362
“Meth” see Methamphetamine
(see also: Methadone; index fn 3)
Methadone, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
detoxification during pregnancy, 191–192
excretion in breast milk, 208(t)
lethal dose, 215
opiate analgesic maintenance, xiv, 338
benefits, 346–347
benefits for adolescent girls during pregnancy,
   190–191, 190(fn 19), 338, 346–347
harm reduction, 346
problems, 346–347
overdoses, 347
poisonings, 347
screening for prenatal exposure, 199
teratogenesis and, 190
unintentional childhood poisonings, 215–216,
   347
use by children and adolescents, 4(fn 3)
withdrawal syndrome, 341(fn 29), 346
management, 342(fn 30)
(see also Opiate Analgesics)
Methamphetamine, 44(t, tn)
brand/trade name, 44(t)
common street names, 44(t)
criminal gang involvement in production and
   commerce, 46, 46(fn 5)
crystal form, 43(fn 2)
administration
   smoking, 43(fn 2), 45, 45(fn 3)
damage to nasal mucosa, 45(fn 3)
purity, 43(fn 2)
derivation of MDMA, 92
duration of action, 46
formulas for production, 46, 46(fn 6)
heart disease/failure and, 50
high risk group, Native Hawaiians, 50(fn 15)
“Mom-and-Pop Meth Lab”, ix
   needle-stick injuries and, 212, 212(fn 28)
secondhand exposure to methamphetamine
   and, 211–212
Montana Meth Project, 332
neurotoxicity and, 48(fn 10), 50(fn 13), 230
memory impairment, 231, 235–236
powder form, 43(fn 2)
administration
   intranasal insufflation, 43(fn 2)
intravenous injection, 43(fn 2)
oral ingestion, 43(fn 2)
rectal insertion, 46(fn 7)
purity, 43(fn 2)
“run”, 50
source country, 46(fn 5)
toxicity, 48–53

associated with accidental needle-stick injuries, 202(fig), 212, 212(fn 28)
associated with exposure to secondhand smoke, 211–212
associated with improper preparation, 46, 46(fn 6)
types of craving and, 167
typical North American user, 45(fn 4)
use by North American adolescents, 46–47
Canadian adolescents and young adults, 47
gay and bisexual adolescent boys, 45
rectal insertion, 46(fn 7)
girls, 45, 46, 46(fn 8)
during pregnancy, 196
lesbian adolescent girls, 46
high school students, 47
of mixed continental descent, 46
of Native descent, 47, 173
(see also Amphetamines)

Methanol, 6(t)
use to extract crude coca paste, 62(fn 34)
(see also Volatile Solvents and Inhalants)

Methcathinone, 44(t)
(see also Psychostimulants)

5-Methoxy-N,N-diisopropyltryptamine, 90(t)

Methylbenzene see Toluene

Methylecgonidine, 63(fn 35)

3,4-Methylenedioxymethamphetamine, 90(t)

3,4-Methylenedioxymethylamphetamine, 90(t)

3,4-MDMA see MDMA

Methylenedioxymethamphetamine (MDMA), 89–94
chemically derived from, 92
combined use with LSD, 175(fn 12)
combined use with flunitrazepam, 26(fn 30)
combined use with GHB, 29, 32
cross-tolerance, 97
desired effects, 26(fn 30), 92
ease of obtaining by adolescents, 91
GHB overdosage and, 32
general pharmacology, 92–94
mechanism of action, 92
overdosage, 93–94
death and, 93–94
associated risk factors, 94
cause, 93
prodromal signs and symptoms, 93
serotonin syndrome and, 93
physical dependence, 93

psychological dependence, 93
source countries, 91
tolerance, 93
cross-tolerance, 97
toxicities, 93–94
acute toxicities, 93–94
chronic toxicities, 93
neurotoxicity, 93, 93(fn 5), 230
associated risk factors, 93(fn 5)
mechanism, 93
memory impairment, 93(fn 5), 231, 236
unintentional poisoning among infants and toddlers, 94, 218

use
among adolescents, 91–92
North American adolescents of African descent, 91
among high school students, 91
among homeless youth, 91
among gay youth, 91, 92
circuit parties and, 92
correlation with unprotected sex, 92
among lesbian youth, 91, 92
as an appetite suppressant, 92
clubbing and, 89
factors associated with, 91
history of, 89
to enhance sexual experiences, 92
raves and, 89
withdrawal syndrome, 93
characteristics, 93
(see also: Amphetamine-Like Psychodelics; Psychodelics)

N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanimine, 90(t)

Methylphenidate, 44(t, tn)
state-dependent learning and, 231, 231(fn 11)
use in treatment of A-D/HD, 43, 226
(see also Psychostimulants)

4-Methylthioamphetamine, 90(t)

Mexican Heroin, 7
purity, 8(fn 7)
(see also: Black Tar Heroin; Mexico)

Mexican Mafia see Criminal Gangs

“Mexican Valium” see Flunitrazepam

Mexico
production of methamphetamine, 46, 46(fn 5)
risky behavior by visiting adolescents
binge drinking, 17
drinking and driving, 17
Mexico (Continued)
source country for black tar heroin, 7
source country for cannabis, 98
source country for flunitrazepam, 26(fn 30)
source country for heroin, 7
source country for kreteks, 73
source country for methamphetamine, 46(fn 5)
source country for MDMA, 91
“Miaow” see Mephedrone

Michigan Alcoholism Screening Test (MAST),
278–280, 278(fn 22), 279(t)
detection of AUDs among adolescents, 278
reliability, 280
scoring, 279–280, 279(t)
sensitivity, 280
specificity, 280
validity, 280
(see also: B-MAST; SMAST)

“Miccies” see Chloral Hydrate

Midazolam, 6(t)
brand/trade names, 6(t)
respiratory depression and, 29
teratogenesis and, 189
(see also Benzodiazepines)

Miltown® see Meprobamate

“45-Minute Trip” see N,N-Dimethyltryptamine

Miscellaneous Psychodelics, 87, 89(fig), 97
(see also: Cannabis; PCP; Psychodelics)

“Mitsubishi” see Paramethoxyamphetamine

Mixed Amphetamines, ix, 44(t, tn, tn c)
brand/trade name, 44(t)
common street names, 44(t)
contents, 44(tn b, c)
use in treatment of A-D/HD, 43
(see also Amphetamines)

Modafinil, 44(t, tn d)
(see also Psychostimulants)

Mogadon® see Nitrazepam

“Moggies” see Nitrazepam

“Mom-and-Pop Meth Lab”, ix
needle-stick injuries and, 212, 212(fn 28)
secondhand exposure to methamphetamine and, 211–212

Montana Meth Project, 332

“Moonshine” see Alcohol

“Mormon Tea” see Ephedrine

“Morning Glory” see Lysergic Acid Amide

Morning Glory Seeds see Lysergic Acid Amide

“Moroccan Kif”, 98(fn 10)
(see also Cannabis)

“Morph” see Morphine

Morphine, viii, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
lethal dose, 215
screening for prenatal exposure, 199
teratogenesis and, 190
unintentional childhood poisonings, 215
(see also Opiate Analgesics)

M.O.S.® see Morphine

Mothers see Parents

Mothers Against Drunk Driving, 337

“Mother’s Little Helper” see Diazepam

Motivation see Learning

Motor Vehicle Crashes
alcohol use and, 13, 24(fig)
cannabis use and, 104, 106–107, 106–107(fn 30)
combined alcohol and cannabis use and, 105, 106(fn 29)
recommendation for screening of adolescent drivers, 248

“MPH” see Methylphenidate

“MS” see Morphine

MS Contin® see Morphine

“4-MTA” see 4-Methylthioamphetamine

Multiple Diagnosis see Dual Diagnosis

Multiple Drug Use see Poly Drug Use

Multiple Model Theory see Interactive Models of Nonmedical Drug Use

Munchauen By Proxy, 214

Murder see Homicide

“Murder 8” see Fentanyl

“Murder One”, 62(fn 33)

“Muskatbaum” see Nutmeg

Muslims
alcohol abstention, 14(fn 16)

N

Nalbuphine, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
(see also Opiate Analgesics)

Naloxone, 341
antidote for opiate analgesic overdosage, xiv, 10–11, 338, 340, 341
combination with pentazocine, 339–340

Naltrexone
blocking of analgesia provided by opiate analgesics, 344–345
common adverse effects, 344
liver damage warning, 344
use for treatment of alcohol dependence, 338
adjunct to psychotherapy, 344
use for treatment of opiate analgesic
dependency, 338, 345–346
compliance, 345–346
efficacy, 345–346
“Nappien” see Zopidem
Narcan® see Naloxone
Nasal Snuff, 81(t)
(see also Tobacco, Smokeless)
National Youth Anti-Drug Media Campaign, 318(fn 1)
Native Americans
absenteeism from school, 3(fn 1)
dual tobacco use see polyuse of tobacco
fetal alcohol syndrome and, 20, 241(fn 22)
illicit commerce in tobacco, 74(fn 55)
methamphetamine use and, 47
polyuse of tobacco, 70(fn 49), 71(fn 51)
poverty level, 3(fn 1)
school drop-out rates, 3(fn 1)
source of data bias, 3
tobacco use, 71(fn 51)
volatile solvent and inhalant use, 34(fn 42), 36
(see also North American Adolescents of Native
Descent)
Nat Sherman® see Cigarettes
Natural History of Alcoholism, 128–129
Natural History of Drug Use, 127–128
antisocial personality and, 128
North American youth of African descent, 128
religiosity and, 128
Viet Nam war veterans, 128
Natural History of Drug Use from Adolescence to
the Mid-30s and, 129–130
application to treatment, 130
self-medication and, 130
Natural History Theories of Drug and Substance
Use, 127–130
Needle Exchange Programs, 320, 327(fn 26)
Nembutal® see Pentobarbital
“Nembs” see Pentobarbital
“Nemesis” see Piperazine Derivatives
Neonate
Apgar score and, 190(fn 18), 191(t)
effect of opiate analgesic use by mothers, 190
criteria for urine testing, 182(t)
daily breast milk consumption by, 210(tn a)
declaration, xiii(fn 13)
drug screening, 178, 182(t), 199–200
opiate analgesic withdrawal syndrome, 190–191
methadone detoxification during pregnancy,
191–192
signs and symptoms, 190
screening for FAS / FASD, 187–188
psychostimulant effects as a result of maternal
cocaine use near term, 195
(see also: Breast Milk; Teratogenesis)
Neurobiology and Pathophysiology of Addiction,
130–131
(see also Theories of Adolescent Drug and
Substance Use)
Neuronal Apoptosis
definition, 20(fn 22)
fetal alcohol syndrome/fetal alcohol spectrum
disorder and, 20
Neurotoxicity
alcohol and, 232
cocaine and, 230
LSD and, 230
methamphetamine and, 230, 235–236
MDMA and, 93, 93(fn 5), 230, 236
“New Mexico Sinse” see Cannabis
Newport® see Tobacco Cigarettes, Menthol-
Flavored
“Nexus” see 4-Bromo-2,5-dimethoxyphenethyl-
amine
Nicorette® see Nicotine
Nicotiana rustica see Tobacco
Nicotiana tabacum see Tobacco
Nicotine, 44(t, tn), 68–85
acetylcholine and, 76, 76(fn 57)
bidis tobacco content, 73
combined use with caffeine, 175(fn 12)
concentrations in breast milk, 80
excretion in breast milk, 208(t)
facilitation of learning, 227
fatal dose, 78
general pharmacology, 75–85
kretek tobacco content, 73
mechanism of action, 75–76, 77(fig)
metabolism by smokers, 83
natural source, 68
nicotinic acetylcholine receptors, 76, 76(fn 58,
59), 77(fig)
genetic influence on, 76
physical dependence, 82–83
genetic influence, 76
mechanisms, 82(fn 67)
mediated by dopamine release, 82(fn 67)
nicotinic receptor subunits and, 76
Nicotine (Continued)
poisoning, 77, 78
fatal dose, 78
signs and symptoms, 78
psychological dependence, 82
psychostimulants commonly used by children and adolescents, 45(fig)
reasons for use, 226
relapsed use
craving and, 84, 84(fn 69)
genetic influence and, 76, 84(fn 70), 85
replacement products, 80, 340, 347
relief of nicotine withdrawal symptoms, 84
use based on harm reduction, 346
replacement therapy, 84, 347–348
combination therapy, 347
efficacy, 347
North American adolescents of African
descent and, 347
North American adolescents of European
descent and, 347
screening for prenatal exposure, 199
self-medication and, 292(fn 8), 301, 311(t)
tobacco cessation programs and, xiv, 347–348
tobacco leaf content, 69
tolerance, 83
toxicity, 76–78
death, 78
in combination with other chemicals in
tobacco smoke, 78
mental disorders associated with use, 299(t)
unintentional poisoning, 78
use during pregnancy, 197
reasons for use, 197(fn 20)
w ood alcohol condrome, 83–84
future research questions, 85
management, 342
signs and symptoms, 83–84
craving among girls, 84
intensity among adolescents with dual
diagnosis, 84
relapsed use and, 84(fn 69)
most common symptom among adoles-
cents, 83(fn 68)
relationship to nicotine blood concentra-
tions, 84, 84(fn 70)
(see also: Psychostimulants; Tobacco)
Nicotrol® see Nicotine
Nitrazepam, 6(t)
brand/trade names, 6(t)
common street names, 6(t)
(see also Benzodiazepines)
“Nitrous” see Nitrous Oxide
Nitrous Oxide, 6(t), 33
common street names, 6(t)
commonly abused volatile solvents and inhal-
ants, 34
use by anesthetists, 34(fn 39)
(see also Volatile Solvents and Inhalants)
Noctec® see Chloral Hydrate
Nonabusable Psychotropic, vii(fig), viii(t)
classification, viii(t)
definition, vii(fig 1)
Nonhydrogenated Hydrocarbons, 39(fn 45)
fatal cardiac dysrhythmias and, 39(fn 45)
(see also Volatile Solvents and Inhalants)
Nonuse see Patterns of Drug and Substance Use
(see also Abstinence)
North American Adolescents of African Descent
cannabis use, 99
incidence of FAS / FASD, 184
leading cause of death, 118
menthol-flavored tobacco use, 71–72
advertising effects, 72
generational effects, 72(fn 52)
reasons for use, 72
(see also tobacco use)
MDMA use, 91
natural history of drug use and, 128
school dropout rate, 337(fn 25)
tobacco use, 71
effect of smoking behavior of parents, 72
volatile solvent and inhalant use, 34(fn 41)
use of nicotine replacement therapy, 347
(see also: Adolescent; Bisexual Adolescent Boys
and Young Adults; Gays; High
School Students; Lesbian Adolescent Girls)
North American Adolescents of Asian Descent
Asian flush, alcohol use and, 13
school dropout rate, 337(fn 25)
volatile solvent and inhalant use, 34(fn 41)
(see also: Adolescent; Bisexual Adolescent
Boys and Young Adults; Gays;
High School Students; Lesbian
Adolescent Girls)
North American Adolescents of European Descent
flunitrazepam use, 26(fn 30)
ketamine use, 109(fn 33)
leading cause of death, 118
problem behavior related to energy drink use, 17
*problem behavior theory: a field theory of problem drinking* and, 161
school dropout rate, 337(fn 25)
tobacco use, 70, 71(t)
  polyuse of tobacco, 70
use of nicotine replacement therapy, 347
volatile solvent and inhalant use and binge drinking, 17(fn 19)
(see also: Adolescent; Bisexual Adolescent Boys and Young Adults; Gays; High School Students; Lesbian Adolescent Girls)

**North American Adolescents of Hispanic Descent**
acclimation-related stress and, 167–168
cannabis use, 99(fn 13)
flunitrazepam use, 26(fn 30)
heroin use, 7, 7(fn 5)
incidence of binge drinking, 17
incidence of drinking while on school property, 15(fn 17)
*orthogonal cultural identification theory* and, 162–163
PCP use, 110
  combined with embalming fluid or formaldehyde, 110
*problem behavior theory: a field theory of problem drinking* and, 161
school dropout rate, 337(fn 25)
smoking behavior of parents and tobacco use, 72
*structural family systems theory* and, 157–158
(see also: Adolescent; Bisexual Adolescent Boys and Young Adults; Gays; High School Students; Lesbian Adolescent Girls)

**North American Adolescents of Native Descent**
ceremonies and rituals, 159(fn 13)
dual tobacco use, 70(fn 49), 71(fn 51)
*ego-self theory of substance dependence* and, 138
incidence of alcoholism, 24(fn 26)
incidence of FAS / FASD, 184, 187(t), 241(fn 22)
methamphetamine use, 47
*orthogonal cultural identification theory* and, 162–163
pregnancy and ethical/legal issues, 175(fn 11)
*problem behavior theory: a field theory of problem drinking* and, 161
school-based prevention programs, 334(fn 20)
school dropout rate, 337(fn 25)
teratogenesis risk, 172–173
  risk factors for alcohol use during pregnancy, 189(t)
tobacco use, 71(fn 51)
  polyuse of tobacco, 70(fn 49)
volatile solvent and inhalant use, 34(fn 42), 36
(see also: Adolescent; Bisexual Adolescent Boys and Young Adults; Gays; High School Students; Lesbian Adolescent Girls; Native Americans)

“Nose Candy” see Cocaine
“Nos Moscada” see Nutmeg
Nubain® see Nalbuphine
“Nubian” see Nalbuphine
Numorphan® see Oxymorphone
Nutmeg, 90(t)
  derivation of MDMA, 92
Nuvigil® see Armadafinil

O

Obenix® see Phentermine
“5-OH-DMT” see 5-Hydroxy-N,N-dimethyltryptamine

“Oiling”
definition, 35

ODD see Oppositional Defiant Disorder
OMDs see Other Mental Disorders

Opiate Analgesics, 4–11
  adulterants, 10, 12(tn)
  chemoreceptor trigger zone, 9
classification, viii(t), 5(t)
cognitive impairment, 11(t)
criminal gang involvement, 8, 8(fn 8)
ease of obtaining by adolescents, 7
ease of obtaining by high school students, 7(fn 4)
excretion in breast milk, 208(t)
general pharmacology, 9–13
internet purchase, 7
intranasal insufflation, 4
toxicity, 9
intravenous use
toxicity, 9–10, 12(t)
mechanism of action, 9
*natural history of drug use* and, 128
overdose, 10–11, 14(t)
  involvement of other drugs and substances of abuse, 11
  treatment, 10–11, 340–341
Opiate Analgesics (Continued)

pathological learning model of addiction and, 130
physical dependence, 10, 11(t)
prescription opiate analgesics, 7, 7(fn 4)
psychological dependence, 10, 11(t)
reasons for use/abuse, 7
receptors, 9,10(fig)
location in central nervous system, 9, 10(fig)
relapsed use, 10
self-medication and, 311(t)
sites of action, 9, 10(fig)
signs and symptoms of poisoning among children, 215
street names, 5(t)
teratogenesis and, 190–192
neonatal opiate analgesic dependence, 190–191
neonatal opiate analgesic withdrawal syndrome, 190, 191–192
ocular morbidity, 190
theory of adolescent psychological individuation and, 139, 140
theory of object relations and adolescent compulsive drug use and, 142
toxicity, 9–11, 11(t), 12(t), 13(t), 14(t)
acute, 11(t)
mental disorders, 299(t)
chronic, 11(t)
direct, 9, 11(t)
indirect, 9–10, 12(t)
adquired immune deficiency syndrome, 9
hepatitis, 9, 12(t)
human immunodeficiency virus infection, 9, 12(t)
talc granulomas, 9, 12(tn)
unintentional childhood poisonings, 215–216
use by children and adolescents, 4, 6–7
during pregnancy, 190
mental disorders and, 299(t)
withdrawal syndrome, 10, 13(t)
methadone detoxification during pregnancy, 191–192
neonates and, 190, 191–192
self-management with GHB, 29
severity, 11(fn 13)
signs and symptoms, 13(t)
(see also Psychodepressants)

Opiate Dependency Programs see Methadone Maintenance

Opium, 5(t)
derivatives, 4, 4(fn 2)
Papaver somniferum, 4
(see also Opiate Analgesics)

Oppositional Defiant Disorder (ODD)
cocaine use during pregnancy and, 194
(see also Dual Diagnosis)

“Oranges” see Mixed Amphetamines

Organized Crime Syndicates see Criminal Gangs

Orthogonal Cultural Identification Theory, 162–163
North American adolescents of Hispanic descent and, 162–163
North American adolescents of Native descent and, 162–163

Other Mental Disorders (OMDs)
antecedents of SUDs, 289, 289(fn 2), 291(fig)
commonly involved with dual diagnosis, 292(t)
consequences of SUDs, 289, 289(fn 2), 291(fig)
(see also: Dual Diagnosis; SUDs)

Outlaw Motorcycle Gangs see Criminal Gangs

Overdosage
amphetamines, 51, 52–53
benzodiazepines, 29
treatment, 29
GHB, 32
involvement of other drugs and substances of abuse, 32

MDMA, 93–94
death and, 93–94
associated risk factors, 94
cause, 93
prodromal signs and symptoms, 93
serotonin syndrome and, 93

opiate analgesics, 10–11
signs and symptoms, 14(t)
treatment, 10–11

PCP, 113–114
management, 114
volatile solvents and inhalants, 41
(see also: Poisoning; Unintentional Childhood Poisonings)

Oxazepam, 6(t)
brand/trade names, 6(t)
teratogenesis and, 189
(see also Benzodiazepines)

Oxycodone, 5(t)
brand/trade names, 5(t)
combined use with cocaine, 175(fn 12)
common street names, 5(t)
excretion in breast milk, 208(t)

teratogenesis and, 190

unintentional childhood poisonings, 215

use by children and adolescents, 4(fn 3)

(see also Opiate Analgesics)

OxyContin® see Oxycodone

“Oxycotton” see Oxycodone

Oxymorphone, 5(t)

brand/trade names, 5(t)

common street names, 5(t)

(see also Opiate Analgesics)

P

“Paan” see Betel Cutch

Paint Thinner, 32

commonly abused volatile solvents

and inhalants, 34

(see also Volatile Solvents and Inhalants)

“Painting”

definition, 35

PALS, 329

“Panama Gold” see Cannabis

Papaver Somniferum see Opium

“Pappas” see Flunitrazepam

Paral® see Paraldehyde

Paraldehyde, 6(t)

brand/trade names, 6(t)

(see also Sedative-Hypnotics)

Paramethoxyamphetamine, 90(t)

Parents

attitude toward drug and substance use, 224(fig)

cocaine use and parent-child teaching

interactions, 222

definition, 222(fn 1)

drug and substance use, 224(fig)

child abuse and, 295

cost neglect and, xii(fn 9)

family violence and, xii(fn 9)

good parenting and academic achievement, 222

parental influence

effect of smoking behavior, 72

family interactional theory of adolescent drug

use, 163

parental modeling

circumplex model of marriage and family

therapy and, 157, 157(fn 10)

role in primary prevention, 323

(see also: Exposure to the Drugs and Substances

of Abuse; Family; Pregnancy)

Passive Smoking see Secondhand Smoke

Pathological Learning Model of Addiction, 130

Patterns of Drug and Substance Use, ix(fig), 317

alcohol use and increasing harm, 15(fig)

controlled use, 317, 318(fig)

prevention strategies and, 318(fig)

PCP see Phencyclidine

“PeaCe Pill” see Phencyclidine

Peer Group Therapy, 350

“Pellets”, 82(t)

(see also Tobacco, Smokeless, Dissolvable)

Pemoline, 44(t)

(see also Psychostimulants)

“Penny Cleaning”

definition, 35

Pentazocine, 5(t)

brand/trade names, 5(t)

combination with naloxone, 339–340

common street names, 5(t)

teratogenic risk, 190

(see also Opiate Analgesics)

Pentobarbital, 5(t)

brand/trade names, 5(t)

common street names, 5(t)

teratogenic risk, 188–189

(see also Barbiturates)

Pentothal® see Thiopental

“Pep Pills” see Amphetamines

Perception see Learning

“Percs” see Oxycodone

“Perc-O-Pop” see Fentanyl

Personality Theories of Drug and Substance Use, 132–147

“Petro” see Gasoline

“Petrol” see Gasoline

Peyote see Mescaline

Phantasticants see Psychodelics

“Pharming”

benzodiazepine use and, 26

definition, 12(fn 14)

sedative-hypnotic use and, 12, 12(fn 14)

Pharmacotherapy, 338–348

for alcohol abstinence maintenance, 343–345

for alcohol withdrawal syndrome, 341–342

for benzodiazepine overdose, 340–341

for cocaine withdrawal syndrome, 342

for dual diagnosis, 348

for nicotine maintenance, 347

for nicotine withdrawal syndrome, 342

for opiate analgesic abstinence maintenance, 345–346
Pharmacotherapy (Continued)
for opiate analgesic maintenance, 346–347
for opiate analgesic overdosage, 340–341
for tobacco smoking cessation, 347–348
multimodal therapy and, 321(fig), 338(fn 27)
(see also: Dual Diagnosis; Treatment)
Phencyclidine (PCP), 90(t), 109–114
alcohol-like disinhibitory euphoria, 110, 112
combined with embalming fluid, 110
combined with formaldehyde, 110
ease of obtaining by adolescents, 110
excretion in breast milk, 209(t)
fatalities and, 113–114
“fry”, “illy”, or “wet”, 110
general pharmacology, 110–114
history, 109
Hell’s Angeles motorcycle gan and, 109
onset and duration of actions, 111
overdosage, 113–114
fatalities, 113–114
management, 114
psychological dependence, 113
routes of administration, 109
screening for prenatal exposure, 199
suicide and, 113–114
superhuman strength and, 112
teratogenesis and, 199
tolerance, 113
toxicities, 111–114
aggressive and violent behaviors, 110, 112,
113–114
contexts of behavior, 112
amnesia, 111–112, 111(fn 35)
associated with higher dosages, 111
associated with lower dosages, 111
“bad trips”, 112
associated with adulterants, 112
delusional and mood disorders, 112–113
characteristic signs and symptoms, 112–113
overdosage and, 112
psychosis, 110, 113
subjective effects, 111
teratogenesis and, 113
unintentional poisoning
signs and symptoms among children, 113
use by adolescents, 109–110
adolescents of Hispanic descent, 110, 112
machismo and, 112
high school students, 110
problems with determining usage, 109
Phendimetrazine, 44(t)
(see also Psychostimulants)
Phenethylamines see Amphetamine-Like Psychodelics
“Pheno” see Phenobarbital
Phenobarbital, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
pharmacological management of seizure disorders, 230–231, 231(fn 10)
teratogenesis and, 188–189
use for management of the GHB withdrawal syndrome, 32
(see also Barbiturates)
Phentermine, 44(t)
(see also Psychostimulants)
Physical Abuse/Neglect
associated with drug and substance use during pregnancy, 175(fn 11)
incidence, 305
involvement of parents or teachers, 295, 305
related deaths, 305
(see also: Family Violence; Murder; Physical Assault; Sexual Assault)
Physical Assault
alcohol and, viii, 20, 22(t)
amphetamines and, viii
cocaine and, viii
PCP and, viii
(see also: Family Violence; Murder; Physical Abuse/Neglect; Sexual Assault)
Physical Dependence, vii(fig 1)
alcohol use and, 22–23
amphetamine use and, 52
benzodiazepine use and, 27–28
caffeine use and, 60–61
cannabis use and, 108, 108(fn 32)
methamphetamine use and, 52
MDMA use and, 93
nicotine use and, 82–83
opiate analgesics use and, 10, 11(t)
(see also: Compulsive Use; Tolerance; Withdrawal Syndrome)
“Pinks” see Secobarbital
Piperazine Derivatives, 90(t), 97
Piptadina peregrine, 94
“Pizza Toppings” see Psilocin
“Plug” see Tobacco
“PMA” see Paramethoxyamphetamine Poisoning
nicotine, 77, 78
volatile solvents and inhalants, 34(fn 43)
(see also: Suicide; Unintentional Childhood Poisonings)

Poly Drug Use
common combinations, 175(fn 12)
during pregnancy, 236(fn 17)
exacerbation of memory impairment, 234–235, 236
flunitrazepam and, 26(fn 30)
MDMA and, 91
predictive model of adolescent use of the drugs and substances of abuse and, 150
theory of drug subculture and, 15

Polyuse of Drugs see Poly Drug Use
Polyuse of Tobacco, 70–71
North American adolescents of European descent, 70, 71(t)
North American adolescents of Native descent, 70(fn 49), 71(fn 51)
(see also Tobacco)
“Poor Man’s Cocaine” see Methamphetamine
“Poor Man’s Heroin” see Oxycodone
Poschl Lowen-Prise® see Tobacco, Smokeless Snuff
POSIT see Problem Oriented Screening Instrument for Teenagers

Positive Action Program, 329

Posttraumatic Stress Disorder (PTSD)
dual diagnosis and, 295–296
“Pot” see Marijuana

Potency
definition, 88
of psychodelics, 88, 88(fn 2)
LSD, 88(fn 2)
mescaline, 88(fn 2)
psilocybin, 88(fn 2)
“Powder” see Cocaine

Predictive Model of Adolescent Use of the Drugs and Substances of Abuse, 150

Pregnancy
dual diagnosis and, 291
FDA pregnancy codes, 174(t), 174(fn 8)
fetotoxicity, 172–200
definition, 172(fn 6)
human gestational development, 180–181(t)
incidence/prevalence of drug and substance use during, 174–175
alcohol and, 183
risk factors associated with use, 189(t)
cocaine and, 193–194
legal/ethical issues, 175(fn 11)
methamphetamine and, 196
nicotine (tobacco smoke) and, 197
reasons for use, 197(fn 20)
paucity of data, 174
polyuse, 175(fn 12)
placental drug transfer, 178(fig)
preeclampsia
smokeless tobacco and, 197
smoking tobacco and, 197
recommendation for psychometric screening of pregnant adolescents, 248
transfer of drugs and substances of abuse across the placenta, 178(fig)
(see also: Prenatal Drug and Substance Exposure; Teratogenesis)

Prelu-2® see Phendimetrazine

Prenatal Drug and Substance Exposure, 172–200
screening, 178, 182(t), 187–188, 199–200
ethical/legal questions, 175(fn 11), 200
North American adolescents of African descent and, 200
sample source, 199
(see also: Pregnancy; Teratogenesis)

Prescription Opiate Analgesics see Opiate Analgesics

Prevention, 317–362
multimodal approaches, 320–321, 321(fig)
primary prevention, 319, 323–337
affective educational/social competency model, 326, 328–329
assumptions, 328
lack of focus on drugs and substances of abuse, 326(fn 8), 328
Positive Action Program, 329
lack of focus on drugs and substances of abuse, 329(fn 11)
themes, 329
self-esteem, 328
successful program components, 329
teachers and, 328
values clarification, 328
alternatives model, 326, 327(t)
alternative activities, 326, 327(t)
assumptions, 326
efficacy, 326
lack of focus on drugs and substances of abuse, 326(fn 8)
self-esteem and, 326, 327(t)
Prevention (Continued)

efficacy, 321(fig)
harm and, 318(fig)
information only model, 325–326
assumptions, 324
efficacy, 325–326
teachers and, 325
inoculations, 323, 329
definition, 323(fn 4)
lack of political or social resolve, 331–332
tobacco use and, 332, 332(fn 17, 18)
underfunding, 331(fn 16)
Montana Meth Project, 332
reasons for failure, 323–324, 331–332
lack of appropriate focus and goals,
323–324
lack of appropriate theory, 324
lack of political or social resolve, 331–332,
331(fn 16)
school-based programs, 321(fig), 332–337
drug-free zones, 335–336, 336(fn 22, 23)
lack of efficacy, 318(fn 1), 333–334,
333(fn 19), 334(fn 20)
limitations, 333, 333(t)
optimization criteria, 334
North American children and adolescents of
Native descent, 334(fn 20)
schools without drugs, 335(t)
tobacco policy, 336(fn 22)
social environmental/learning model, 329–331
assumptions, 329
Drug Abuse Resistance Education, 329
efficacy, 329(fn 13), 333(fn 19), 334
extent of use, 329(fn 13)
efficacy, 329, 330–331
inoculation, 323, 323(fn 4), 329
Just Say No, 329
Life Skills Training, 329
Lions-Quest Skills for Adolescence, 329
peer facilitation, 330, 330(fn 14)
synonyms, 329(fn 12)
variables amenable to, 319(t)
Vermont Anti-Smoking Campaign, 332
secondary prevention, 320, 337–338
efficacy, 321(fig)

safe injection sites, 337, 337(fn 26)
Mothers Against Drunk Driving, 337
Students Against Drunk Driving, 337
variables amenable to, 319(t)
supply reduction, 128
tertiary prevention, 320, 338–362
Alcoholics Anonymous, 357–359, 357(fn 46),
358(t)
efficacy, 321(fig)
employee assistance programs, 320
harm and, 318(fig)
multimodal approaches, 320–321, 321(fig)
pharmacotherapy, 338–348
psychotherapy and counseling, 348–357
relapse prevention, 359–361, 360(fig)
variables amenable to, 319(t)
unanswered questions, 331
(see also: Quick-Screen Psychometric Tests;
Theories of Adolescent Drug and
Substance Use; Treatment)

Primary Prevention see Prevention
Prime Time® see Tobacco Cigarillos
Problem Behavior Theory: A Field Theory of
Problem Drinking, 161–162
North American adolescents of European
descent, 161
North American adolescents of Hispanic
descent, 161
North American adolescents of Native
descent, 161
Problem Oriented Screening Instrument for Teen-
agers (POSIT), 280–281, 281(t)
detection of AUDs among adolescents, 280
detection of SUDs among adolescents, 280
eficacy, 280
reliability, 281
scoring, 280, 281(t)
sensitivity, 280–281
specificity, 280–281
use with adolescent mothers, 281
use with incarcerated adolescents, 281
validity, 281
Prolintane, 44(t, tn e)
(see also Psychostimulants)
Propane, 6(t)
hypoxia and, 39
nonhalogenated hydrocarbon, 39(fn 45)
products containing, 33, 33(fn 37)
use related fatality, 38–39
(see Volatile Solvents and Inhalants)
Propoxyphene, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
excretion in breast milk, 208(t)
overdosage
   signs and symptoms, 14(t)
   removal from market, 6(tn e)
   (see also Opiate Analgesics)
ProSom® see Estazolam
Provigil® see Modafinil
Pseudoephedrine
   production in China and India, 46(fn 5)
   use in the production of methamphetamine, 46(fn 5)
Psilocin, 90(t)
   natural source, 94
   (see also: LSD-Like Psychodelics; Psilocybin)
Psilocybe Mushrooms, 94
Psilocybin, 90(t)
   cross-tolerance, 97
   natural source, 94
   potency, 88(fn 2)
   (see also: LSD-Like Psychodelics; Psilocin)
Psychodelics see Psychodelics
definition, 87
Psychodelics, 87–114
   biological theory of sensation seeking and, 122
classification, viii(t), 87, 89(fig)
   amphetamine-like, 87, 89–94
      common street names, 90(t)
      generic names, 90(t)
      work of Alexander Shulgin, 89
      (see also MDMA)
   LSD-like, 87, 94–97
      chemical relationship to serotonin, 94
      (see also LSD)
miscellaneous, 87, 97–114
      (see also: Cannabis; PCP)
definition, 87
effects on learning, 226–231
effects on memory, 231–236
mental disorders associated with use, 299(t)
natural history of drug use and, 128
patterns of use, 114
potency, 88, 88(fn 2)
psychological dependence, 88
reasons for use, 114
somatosensory affectional deprivation theory and, 121–122
synesthesia, 100
synonyms, 87, 88(fig)
teratogenesis and, 198–199
theory of object relations and adolescent compulsive drug use and, 142
use
   clubbing and, 88
   future trends, 114(fn 36)
   raves and, 88
   reasons for, 88
   (see also individual psychodelics)
Psychodepressants, 3–41
   biological theory of sensation seeking and, 122
classification, viii(t), 5(t)
effects on learning, 226–231
effects on memory, 231–236
natural history of drug use and, 128
somatosensory affectional deprivation theory and, 122
teratogenesis and, 178–179, 182–182
theory of object relations and adolescent compulsive drug use and, 142
   (see also: individual psychodepressants; Opiate Analgesics; Sedative-Hypnotics; Volatile Solvents and Inhalants)
Psychological Dependence, vii(fig 1)
   alcohol use and, 22–23
   amphetamine use and, 52
   benzodiazepine use and, 27
   caffeine use and, 60–61
   cocaine use and, 68
definition, 22
   methamphetamine use and, 52
   MDMA use and, 93
   nicotine use and, 82
   opiate analgesics use and, 10, 11(t)
   PCP use and, 113
   psychedelic use and, 88
   (see also Habitual Use)
Psychological Theories of Drug and Substance Use, 118(fig), 119(fig), 132–151
   (see also Theories of Adolescent Drug and Substance Use)
Psychometric Questionnaire see Quick-Screen Psychometric Tests
Psychometric Screening Tests see Quick-Screen Psychometric Tests
Psychosis
   alcohol-induced, 21(t), 22(tn a)
   amphetamine-induced, 49, 50, 51, 302
   management, 51
   cannabis-induced, 103(t), 104(fn 20)
   cocaine-induced, 65, 302
dual diagnosis, 292(t), 302–304
Psychosis (Continued)

- LSD-induced, 96, 302
- phencyclidine-induced, 110, 112, 113, 302
- signs and symptoms, 302
  (see also: Dual Diagnosis; Schizophrenia)

Psychosocial Model of Adolescent Drug Involvement see Four-Factor Model of Adolescent Drug Involvement

Psychosocial Theories of Drug and Substance Use, 150–151
  (see also Theories of Adolescent Drug and Substance Use)

Psychostimulants, 43–86
  access by adolescents, 43
  biological theory of sensation seeking and, 122, 123
  classification, viii(t), 44(t)
  commonly used by children and adolescents, 45(fig)
  effects on learning, 226–231
  effects on memory, 231–236
  indirect acting, 48
  natural history of drug use and, 128
  reasons for use, 123, 226
  teratogenesis and, 192–198
  theory of object relations and adolescent compulsive drug use and, 142
  use in the management of A-D/HD, 226
  (see also individual psychostimulants)

Psychotherapy/Counseling, 348–357
  cognitive therapy, 349, 349(t)
  ethnic-specific treatment programs, 356–357
  family therapy, 350–354, 350(fn 38), 352(t)
  gay and lesbian-oriented treatment programs and, 357
  peer group therapy, 350
  short-term residential treatment programs and, 356, 356(t)
  social skills training, 354–355, 354(fn 42, 43)
  therapeutic communities and, 355–356, 355(fn 44)
  (see also: Prevention; Treatment)

Psychotogen see Psychodelics

Psychotomimetics see Psychodelics

Psychotomystics see Psychodelics

Psychotropic
  definition, vii(fig 1)

PTSD see Posttraumatic Stress Disorder

Q
  “Quat” see Cathinone

Quick-Screen Psychometric Tests, 245–288
  basic test statistics, 251–256
  efficacy, 252(t)
  false negative rate, 252(t)
  false positive rate, 252(t)
  negative predictive value, 251, 252(t, tn f)
  positive predictive value, 251, 252(t, tn e)
  sensitivity, 251, 252(t)
  specificity, 251, 252(t)
  test reliability, 254–256
  definition, 254
  internal test consistency, 255
  item reliability, 255–256, 255(fn 10)
  synonyms, 254
  test-retest reliability, 255
  test validity, 252–254
  concurrent validity, 253–254
  content validity, 253
  construct validity, 253
  convergent validity, 253
  criterion-related validity, 254
  definition, 252
  discriminant validity, 253
  divergent validity, 253
  face validity, 254
  predictive validity, 254
  benefits of use, 245

detection of AUDs among adolescents
  AUDIT, 261–262, 262(t), 265–264
  AUDIT-C, 265–267, 266(t)
  B-MAST, 267–268, 268(t)
  CAGE, 268–270, 269(t)
  CRAFFT, 272–273, 273(t)
  MAST, 278–280, 278(fn 22), 279(t)
  POSIT, 280–281, 281(t)
  RAPI, 282–284, 283(t)
  RAPS4, 281–282, 282(t)
  SMAST, 284–285, 285(t)
  T-ACE, 285–286, 286(t)
  TWEAK, 286–288, 287(t)

detection of SUDs among adolescents
  ASSIST, 259–261
  CAST, 270–271, 271(t)
  CRAFFT, 272–273, 273(t)
  CUDIT, 271–272, 272(t)
  DAST, 273–275, 274(t)
  DUDIT, 275–276, 276(t)
  FTND, 276–278
  POSIT, 280–281, 281(t)

importance of screening, 246–248
lack of available tests for children, 258(fn 13)
list, 258, 259(t)
relationship to diagnosis of a AUD or SUD, 246, 247(fig)
selection considerations, 288
tester, 256
   interrater reliability
   test-taker, 256–258
   nontruthful reporting/responses, 245, 246(fn a), 256(fn 11), 257(fn 12)
“Quid” see Betel Cutch

R
Rape see Sexual Assault
RAPI see Rutgers Alcohol Problem Index
Rapid Alcohol Problems Screen, Version 4
(RAPS4), 281–282, 282(t)
detection of AUDs among adolescents, 281
recommendations, 282
scoring, 282, 282(t)
sensitivity, 282
specificity, 282, 282(fn 24)
RAPS4 see Rapid Alcohol Problems Screen, Version 4
Ratio-Codeine® see Codeine
Raves
definition, 89(fn 4)
GHB use and, 30
MDMA use and, 88, 89
psychedelic use and, 88
Reasons for Drug and Substance Use see Theories of Adolescent Drug and Substance Use
Receptors
   for benzodiazepines, 26–27, 27(fig)
   for caffeine, 58, 59(fig)
   for nicotine, 76, 76(fn 58, 59), 77(fig)
   for opiate analgesics, 9, 10(fig)
Recidivism see Relapsed Use
Red Man® see Tobacco, Smokeless, Chewing “Reds” see Secobarbital
“Reefer” see Marijuana Cigarette
Relapse see Relapsed Use
Relapsed Use
dual diagnosis and, 291, 304
evaluation criteria, 361(t)
factors contributing to, 359
nicotine (tobacco), 84, 84(fn 69)
   genetic influence, 76, 84(fn 70), 85
opiate analgesics, 10
prevention, 359–361
rate, 359, 360(fig)
recommendations to minimize, 359–360
(see also Patterns of Drug and Substance Use)
Religiosity
   incomplete mourning theory and, 156
natural history of drug use and, 128
relationship to psychedelic use, 114, 114
   (fn 36)
Restoril® see Temazepam
Resumed Nonuse see Patterns of Drug and Substance Use
(see also Abstinence)
Retrograde Amnesia see Memory
ReVia® see Naltrexone
   “Rich Man’s Drug” see Cocaine
   “Rig” see Hypodermic Needle and Syringe
Right-Brain Model of Adolescent Substance Abuse, 141–142
   application to treatment, 142
   assumptions, 141
   hypotheses, 141
Risky Behavior Paradigm, 123
Ritalin® see Methylphenidate
Rituals
   initiatory model of drug abuse and, 144
   North American adolescents of Native descent and, 159(fn 13)
   role strain theory and, 159, 159(fn 13)
Rivotril® see Clonazepam
Rohypnol® see Flunitrazepam
Role Strain Theory, 158–159
   hypotheses, 158
   initiation and ritual, 159, 159(fn 13)
   North American adolescents of Native descent, 159(fn 13)
   relapse and, 158
Romazicon® see Flumazenil
“Roofies” see Flunitrazepam
“Rs” see Methylphenidate
“Rum Fits” see Delirium Tremens
Runaway Youth
dual diagnosis and, 291, 294
MDMA use and, 91
   source of data bias, 3
(see also Homeless Children and Adolescents)
“Rush”
definition, 8(fn 11)

*Rutgers Alcohol Problem Index* (**RAPI**), 282–284, 283(t)
detection of AUDs among adolescents, 282
reliability, 284
scoring, 283(t), 284
sensitivity, 284
specificity, 284
validity, 284

S

“Sacking”
definition, 35

“Sacred Mushrooms” see Psilocybin
Safe Injection Sites, 337, 337(fn 26)
Salem® see Tobacco Cigarettes, Menthol-Flavored
*Salvia divinorum*, 90(t), 97
use by high school students, 91(tn h)
Sanorex® see Mazindol
Scandinavian Snuff, 81(t)
(see also Tobacco, Smokeless)
Scared Straight, 325
Schizophrenia
cannabis use and, 303–304, 303(fn 17, 18)
dual diagnosis, 292(t), 302–304
incidence, 302
self-medication, 303, 304
(see also: Dual Diagnosis; Psychosis)
Schizophrenomimetics see Psychodelics
“School Boy” see Codeine
Schools, x, x(fn 4)
absenteeism from school
bullying behavior and, x, 295–296, 295(fn 12)
Native Americans and, 3(fn 1)
secondhand tobacco exposure and, 221–222
incidence of drinking while on school property, 15
policies
drug-free zones, 335–336, 336(fn 22, 23)
school without drugs, 335(t)
tobacco policy, 336(fn 22)
school-based prevention programs, 321(fig), 323, 332–337
efficacy, 333–334, 333(fn 19), 334(fn 20)
limitations, 333, 333(t)
optimization criteria, 334
school drop-out
drug and substance abuse and, 3(fn 1), 221, 337
rates for North American adolescents, 3(fn 1), 337(fn 25)

source of data bias, 3
(see also: Learning; Memory; Teachers)
Screening for Drug and Substance Use Disorders, 245–288
constraints to screening, 249(t)
high risk adolescents, 248
importance of screening, 246–248
quick-screen psychometric tests
focus of use, 250(fig)
list, 258, 259(t)
synonyms, 250(fn 5)
test statistics and results, 252(t)
relationship to diagnosis, 246, 247(fig)
(see also: Detecting AUDs among Adolescents; Detecting SUDs among Adolescents)
Secobarbital, 5(t)
brand/trade names, 5(t)
common street names, 5(t)
teratogenesis and, 188–189
(see also Barbiturates)
Seconal® see Secobarbital
Secondary Prevention see Prevention
Secondhand Smoke Exposure, 203, 203(fn 27), 211–213
cannabis and, 211
grow op” and, 211
cocaine and, 211
infant death and, 211
factors affecting related harm, 203, 211
fentanyl and, 213
heroin and, 213
methamphetamine and, 211–212
home-based production and, 211–212
nicotine (tobacco smoke) and, 78, 212–213
absenteeism from school and, 221–222
A-D/HD and, 213
incidence of exposure, 212
risks associated with exposure, 213
sudden infant death syndrome and, 80, 212
unnecessary deaths and, 78(fn 63)
opiate analgesics and, 213
opium and, 213
pulmonary toxicity and, 213
synonyms, 203(fn 27), 212(fn 29)
Sedative-Hypnotics, 11–32
brand/trade names, 5–6(t)
classification, viii(t), 5–6(t)
mental disorders associated with use, 299(t)
natural history of drug use and, 128
“pharming”, 12, 12(fn 14)
street names, 5–6(t)

theory of adolescent psychological individuation
and, 139
(see also: Alcohol; Barbiturates; Benzodiazepines; Z-Drugs)

Seizure Disorders
pharmacological management, 230–231

Self-Esteem
alternatives model and, 326
assumptions of affective educational competency model and, 328
intrapersonal variable, 319(t), 322(fig)
unanticipated consequences of improvement, 328(fn 10)

Self-Help
life process program theory of natural recovery
and, 147–148
(see also: Alcoholics Anonymous; Treatment)

Self-Medication
alcohol and, 137, 138, 295, 298, 311(t)
benzodiazepines and, 298, 311(t)
cocaine and, 137, 300, 311(t)
chronobiological control theory and, 120–121
ego-self theory of substance dependence and, 137–139
existential theory of drug dependence and, 136
GHB and, viii, 29–31, 233(fn 13), 235
(see also Physical Assault)
Sexual Orientation see Bisexual Adolescent Boys and Young Adults; Gays; Lesbian Adolescent Girls
“Sherm Sticks” see “Fry”
“Shit” see Heroin
Shoe Polish
commonly abused volatile solvents and inhalants, 34
(see also Volatile Solvents and Inhalants)
Short Michigan Alcoholism Screening Test (SMAST), 284–285, 285(t)
detection of AUDs among adolescents, 284 recommendations, 285
reliability, 285
scoring, 284, 285(t)
sensitivity, 284–285
specificity, 284–285
validity, 285
(see also: B-MAST; SMAST)
Short-Term Memory see Memory
Short-Term Residential Treatment, 356–356(t)
key program elements, 356(t)
objectives, 356(t)
(see also Psychotherapy/Counseling)
“Shrooms” see Psilocin
Side-Stream Smoke see Secondhand Smoke
SIDS see Sudden Infant Death Syndrome

Sinsemilla
definition, 97
THC concentration, 97, 104
(see also: Cannabis; THC)
“Ska Maria Pastora” see Salvia divinorum
Skoal® see Tobacco, Smokeless, Chewing
Skoal Long Cut Mint® see Tobacco, Smokeless, Dipping
“Sleepers” see Phenobarbital
“Smack” see Heroin
SMART Moves, 329
SMAST see Short Michigan Alcoholism Screening Test
Smokeless Tobacco
American snuff, 81(t)
carcinogens and, 80
“chew” see chewing tobacco
chiping tobacco, 81(t)
“dip” see dipping tobacco
dipping tobacco, 81(t)
dry snuff see nasal snuff
dry snus see nasal snuff
Smokeless Tobacco (Continued)
  high school student use, 71(t), 71(tn c)
  historical pattern of use, 69–70
  lozenges, 82(t)
  nasal snuff, 81(t)
  pellets, 82(t)
  preeclampsia and, 197
  Scandinavian snuff, 81(t)
  “snuff” see nasal snuff
  “snus, American” see American Snuff
  “snus, Swedish” see Scandinavian Snuff
  “spit tobacco” see dipping tobacco
  toxicities
    irritation of the oral mucosa, 80
    oral cancers, 80
    pancreatic cancer, 80
  twisted sticks, 82(t)
  use
    bisexual, gay, and lesbian adolescents,
      70(fn 48)
    boys, 70
    girls, 70
    North American adolescents of European
descent, 71(t)
(see also Tobacco)
“Smokes” see Cigarettes
Smoking see Tobacco
(see also: Cannabis; Opiate Analgesics)
“Smurfs” see Psilocybin
“Sniff” see Acetone
“Sniffing”
definition, 35
“Snorting” see Intranasal Administration
“Snow” see Cocaine
Snuff see Nasal Snuff

Social Control Theories of Drug and Substance
Abuse, 159–160
(see also Theories of Adolescent Drug and
Substance Use)
Social Skill Training, 354–355
use with children and adolescents with bullying
issues, 354(fn 43)
use with children with FAS/FASD, 354(fn 42)
Social Use see Patterns of Drug and Substance Use
Sociological Theories of Drug and Substance
Abuse, 118(fig), 119(fig), 151–168
(see also Theories of Adolescent Drug and
Substance Use)
Sodium Oxybate see GHB
“Soft Drug”, 332, 332(fn 17)

Solvents
  extraction of coca paste from cocaine leaves
    with, 62(fn 34)
  extraction of hashish oil with, 98
  lack of human study data, 37(fn 44)
  method of use, 34–35
  sudden sniffing death, 39–40, 39(fn 45), 40(fn
    46)
  toxicity, 37–41
    accidental injury, 39
    asphyxiation, 39
    chronic toxicities, 40
  signs and symptoms of use, 35(t, tn)
  unintentional poisoning, 34(fn 43)
  use by children and adolescents, 34
    Native American youth, 34(fn 42), 36
(see also: Acetone; Benzene; Gasoline; Paint
Thinner; Toluene; Volatile Solvents and Inhalants)
“Soma” see Amanita muscaria
Soma® see Carisoprodol

Somatosensory Affectional Deprivation Theory of
Drug and Alcohol Use, 121–122
applications to treatment, 122
assumptions, 121
endorphin system and, 122
groups of substance abusers, 122
maternal use of alcohol and fetal effects, 122
Sonata® see Zaleplon
“Special K” see Ketamine
“Speed” see Amphetamines
(see also: Methamphetamine; index fn 3)
“Speedball”, 62(fn 33)
“Spirals” see Alpha-methyltryptamine
Spit Tobacco, 81(t)
(see also Tobacco, Smokeless)
Spray Paint
  commonly abused volatile solvents and
    inhalants, 34
(see also Volatile Solvents and Inhalants)
“Spraying”
definition, 35
“Squaw Tea” see Ephedrine
Stadol® see Butorphanol
“Star” see Methcathinone
Starnoc® see Zaleplon
“Stove Top” see Methamphetamine
“Stove Top Meth” see Methamphetamine
“STP” see 2,5-Dimethoxy-4-methylamphetamine
Strattera® see Atomoxetine
Street Names
amphetamines, 44(t)
barbiturates, 5(t)
benzodiazepines, 5–6(t)
inhalants, 6(t)
miscellaneous psychostimulants, 44(t)
miscellaneous sedative-hypnotics, 6(t)
opiate analgesics, 5(t)
volatile solvents, 6(t)
z-drugs, 6(t)

**Structural Family Systems Theory, Extended**, 157–158
application to treatment, 158
North American adolescents of Hispanic descent and, 157–158

Students Against Drunk Driving, 337
Study Drugs, 227
(see also: Amphetamines; Methylphenidate)

Substance Use Disorders (SUDs)
as antecedents of OMDs, 289, 289(fn 2), 291(fig)
as consequences of OMDs, 289, 289(fn 2), 291(fig)
as contributors to dual diagnosis, 290(fig)
concealment of use, 245, 246(tn a), 256–258, 256(fn 11), 257(fn 12)
North American adolescents of African descent, 245
detection among adolescents with quick-screen psychometric tests
ASSIST, 259–261
CAST, 270–271, 271(t)
CRAFFT, 272–273, 273(t)
CUDIT, 271–272, 272(t)
DAST, 273–275, 274(t)
DUDIT, 275–276, 276(t)
FTND, 276–278
POSIT, 280–281, 281(t)
difficulty detecting among adolescents, 290
screening, 245–248
flowchart, 247(fig)
importance, 246–248
missed diagnoses, 246(t)

SUDs see Substance Use Disorders

Sudden Infant Death Syndrome
maternal tobacco smoking and, 80, 197–198
secondhand tobacco smoke exposure and, 80, 212

Sudden-Sniffing Death
butane and, 40(fn 46)
glue and, viii
volatile solvents and, viii, 39–40, 40(fn 46)

“Suds” see Alcohol

Suicide
alcohol use and, 13, 22(t)
cannabis use and, 105(fn 24), 106
dual diagnosis and, 291
incomplete mourning theory and, 156
LSD use and, 96
PCP use and, 113–114
recommendation for psychometric screening of survivors, 248
theory of object relations and adolescent compulsive drug use and, 142, 143

“Super Labs”
definition, 46(fn 5)

Swedish Snus see Scandinavian Snuff

Sympathomimetics
amphetamines as, 47–48
definition, 47(fn 9)
physiologic action, 47–48(fn 9)

T
“T’s” see Pentazocine
“T3” see Codeine

T-ACE, 285–286, 286(t)
detection of AUDs among adolescents, 285
recommendations, 286
scoring, 285–286, 286(t)
sensitivity, 286
specificity, 286

Take Charge of Your Life, 333
Talwin® see Pentazocine
Talwin-Nx®, 339–340

Tea
caffeine content in various teas, 54(t)
natural sources, 53
(see also Caffeine)

Teachers, x
factors affecting learning at the macro level, 223, 224(fig)
danger of surprising a volatile solvent or inhalant using student, 39
differentiating between drug-induced and organic learning disorders, 222
drug and substance use by teachers and educational outcomes, 223, 224(fig)
insufficient drug and substance abuse knowledge/education, 325, 325(fn 7), 333(t), 336, 336(fn 24)
(see also: Learning; Schools)

Temazepam
brand/trade names, 6(t)
Temazepam (Continued)
common street names, 6(t)
teratogenesis and, 189
(see also Benzodiazepines)
“Temmies” see Nitrazepam
“Tems” see Buprenorphine
Tenuate® see Diethylpropion
Teratogenesis, 172–200
animals studies and, 173
characteristics, 172
cofactors, 173, 175–177, 176(fig)
drug or substance of abuse cofactors, 176, 176(fig), 178(fig)
environmental cofactors, 176(fig), 176–177
fetal cofactors, 176, 176(fig)
maternal cofactors, 175, 176(fig)
placental cofactors, 175–176, 176(fig), 178(fig)
time and, 177, 179(fig), 180–181(t)
fetotoxicity, 172–200
definition, 172(fn 6)
gestational teratogenic susceptibility, 179(fig)
human gestational development, 180–181(t)
incidence, 172–173
North American adolescents of Native descent, 172–173
teratogen, 172(fn 5)
teratogenic potential of the drugs and substances of abuse, 177–199
psychodelics, 198–199
psychodepressants, 178–179, 182–192
psychostimulants, 192–198
thalidomide and, 173, 173(fn 7)
(see also Pregnancy)
Tertiary Prevention see Prevention
(see also Treatment)
Tetrahydrocannabinol (THC), 97, 100
concentration
changes in, 98, 98(fn 9, 12)
factors affecting, 98
in cannabis plant parts, 97
in female cannabis plants, 97
in indica varieties of cannabis, 97
in marijuana, hashish, and hashish oil, 98
in sinsemilla, 97
elimination in regular long-term users, 107
excretion in breast milk, 205(t)
synesthesia, 100
teratogenesis and, 199
(see also: Cannabis; Hashish; Hashish Oil; Marijuana)
“Texas Shoe-Shining”
definition, 35
“Thai Sticks” see Cannabis
Thalidomide, 173, 173(fn 7)
THC see Tetrahydrocannabinol
Theoretical Framework of Developmental Stages in Adolescent Drug Involvement, 153–154
Theories of Adolescent Drug and Substance Use
biological theories, 118(fig), 119(fig), 119–132
natural history, 127–130
genesis of male alcoholism, 127
natural history of alcoholism, 128–129
natural history of drug use, 127–128
natural history of drug use from adolescence to the mid-30s, 129–130
neurobiology, 120–127
biological theory of sensation seeking and optimal catecholamine system activity, 122–124
chronobiological control theory, 120–121
four-circuit neurobehavioral model of addiction, 124–127
loss of control and compulsive drug use see four-circuit neurobehavioral model of addiction
somatosensory affectional deprivation theory, 121–122
neurobiology and pathophysiology, 130–131
pathological learning model of addiction, 130–131
theory of brain emotional systems and addiction, 131
theory of pathophysiological pathways of stress-related addiction, 131
psychological theories, 118(fig), 119(fig), 132–151
personality (eclectic), 132–147
disruptive environment theory, 132–136
go-no-model of substance dependence, 137–139
existential theory of drug dependence, 136–137
initiatory model of drug abuse, 144–145
right-brain model of substance abuse, 141–142
self-medication hypothesis see ego-self theory of substance dependence
theory of adolescent psychological individuation, 139–141
theory of emerging adulthood, extended, 145–147
theory of object relations and compulsive drug use, 142–144
learning theories, 147–150
cognitive-behavioral theory of adolescent chemical dependency, 148–150
life process program theory of natural recovery, 147–148
psychosocial theories, 150–151
four-factor model of adolescent drug involvement, 150–151
predictive model of adolescent use of the drugs and substances of abuse, 150–151
psychosocial model of adolescent drug involvement see four-factor model of adolescent drug involvement
sociological theories, 118(fig), 119(fig), 151–168
acculturation theory, 167–168
criminology and deviance, 151–155
deviance theory: an explanatory model, 154–155
drug subculture theory see theory of drug subcultures, 152–153
the gateway hypothesis see theoretical framework of developmental stages in adolescent drug involvement
theoretical framework of developmental stages in adolescent drug involvement, 153–154
economics, 166–167
alcohol advertising, 166–167
tobacco advertising, 167
family systems, 155–158
circumplex model of marriage and family systems, 156–157
incomplete mourning theory, 155–156
structural family systems theory, extended, 157–158
interactive models, 160–166
biopsychosocial model of adolescent susceptibility to a substance abuse disorder, 164–166
family interactional theory of adolescent drug use, 163
field theory of problem drinking see problem behavior theory
integrative family therapy model, 163–164
interactive models of nonmedical drug use, 160–161
multiple model theory see interactive models of nonmedical drug use
orthogonal cultural identification theory, 162–163
problem behavior theory, 161–162
role strain, 158–159
role strain theory, 158–159
social control, 159–160
social control theory, 160
Theory of Adolescent Psychological Individuation, 139–141
fundamental postulate, 140
numinous factors, 140
Theory of Brain Emotional Systems and Addiction, 131
Theory of Drug Subculture, 152–153
argot, 152
central roles, 152
conduct norms, 153
rituals, 152
Theory of Emerging Adulthood, Extended, 145–147
ages of, 145–147
hypotheses, 145–147
Theory of Object Relations and Adolescent Compulsive Drug Use, 142–144
application to treatment, 143–144
twelve-step programs and, 143
suicide and, 142, 143
Theory of Pathophysiological Pathways of Stress-Related Addiction, 131
Therapeutic Communities, 355–356
abstinence, 356
efficacy, 356
egalitarianism, 355
goals, 355
recommendations for improvement, 356
staff members, 355(fn 44)
treatment mandated by juvenile justice system, 355
(see also Psychotherapy/Counseling)
“The Smart Drug” see Methylphenidate
Thiopental, 5(t)
brand/trade names, 5(t)
(see also Barbiturates)
“Thunder Nectar” see 1,4-Butanediol
“Tic-Tacs” see Mixed Amphetamines
(see also: Zopidem; index fn 3)
“Tina” see Methamphetamine
“TMA” see 3,4,5-Trimethoxyamphetamine
“Toad” see 5-Hydroxy-N,N-dimethyltryptamine
Tobacco
advertising, 167
(see also recommendations for decreasing
tobacco sales to youth)
availability, 332, 332(fn 18)
bidis, 72–73
flavoring, 73
nicotine content, 73
reasons for use by adolescents, 73
source country, 73
use by North American adolescents, 73
cigarettes (see also smoking tobacco)
advertising, 166
combined use with caffeine, 175(fn 12)
high school student use, 71, 71(tn a),
  84(fn 71)
historical pattern of use, 69(fn 47)
menthol-flavored, 71(fn 50)
effects of, 72
North American adolescents of African
descent, 71–72
lung cancer and, 79
reasons for use, 72
natural history of drug use from adolescence
to the mid-30s and, 129–130
nicotine metabolism by smokers, 83,
  84(fn 70)
North American adolescents of European
descent, 70, 71(t)
purchase by high school students, 84(fn 72)
thoretical framework of developmental
stages in adolescent drug
involvement and, 154
cigarillos, 72 (see also smoking tobacco)
attraction for youth, 72
increased use, 72
nicotine content, 72
cigars (see also smoking tobacco)
high school student use, 71, 71(tn b)
increased use, 72
use by North American adolescents of
European descent, 71(t)
classification, viii(t)
dual tobacco use see polyuse of tobacco
East Indian cigarettes see bidis
historical pattern of use, 69(fn 47)
Indonesian cigarettes see kretaks
kretaks, 72–73
availability, 73
clove content, 73
nicotine content, 73
popular brand, 73(fn 53)
use by North American adolescents, 73
lung cancer and, xii(fn 9)
deaths, 79
incidence among men of African descent, 79
mortality risk for men and women, 79
natural source, 68
nicotine content, 69, 73
nicotine metabolism by smokers, 83
nicotine replacement products, 80
nicotine replacement therapy, 84, 347–348
combination therapy, 347
efficacy, 347
North American adolescents of African
descent and, 347
North American adolescents of European
descent and, 347
poly use of tobacco, 70–71
North American adolescents of Native
descent, 70(fn 49), 71(fn 51)
use among adolescents, 71
predictive model of adolescent use of
the drugs and substances of
abuse and, 150
recommendations/regulations for decreasing
tobacco sales to youth, 73–75
Food and Drug Administration regulations,
  74–75, 75(t)
bans on cigarette flavoring, 74
cigarette package warning labels, 74–75
restriction of the distribution, sale, and mar-
ketiing of cigarettes and smokeless
tobacco to children and adolescents,
  74, 75(t)
Vermont Anti-Smoking Campaign, 332
weakness of, 332, 332(fn 18)
(see also: advertising; availability)
smokeless tobacco
American snuff, 81(t)
carcinogens and, 80
“chew” see chewing tobacco
chewing tobacco, 81(t)
“dip” see dipping tobacco
dipping tobacco, 81(t)
dry snuff see nasal snuff
dry snus see nasal snuff
high school student use, 71(t), 71(tn c)
historical pattern of use, 69–70
lozenges, 82(t)
nasal snuff, 81(t)
pellets, 82(t)
preeclampsia and, 197
Scandinavian snuff, 81(t)
“snuff” see nasal snuff
“snus, American” see American Snuff
“snus, Swedish” see Scandinavian Snuff
“spit tobacco” see dipping tobacco
toxicities
irritation of the oral mucosa, 80
oral cancers, 80
pancreatic cancer, 80
twisted sticks, 82(t)
use
bisexual, gay, and lesbian adolescents, 70(fn 48)
boys, 70
girls, 70
North American adolescents of European descent, 71(t)
smoking tobacco
nicotine replacement therapy, 84, 347–348
efficacy, 347
North American adolescents of African descent and, 347
North American adolescents of European descent and, 347
smoking cessation non-nicotine pharmacotherapy
varenicline, 347–348
combined therapy, 348
common adverse effects, 348
efficacy, 348
mechanism of action, 348
suicide warning, 348
toxicities
acute
initial unpleasant experience, 77(fn 60)
chronic
cancers, 79
cardiovascular disease, 79
childhood asthma, 198
pulmonary toxicity
relative risk in comparison to cannabis smoking, 107(fn 31)
teratogenic effects, 79–80
death, 78, 78(fn 63)
due to cancers, 79
due to cardiovascular diseases, 79
due to respiratory diseases, 79
mortality rates for men and women, 79
SIDS, 80, 197–198
spontaneous abortion, 79
use by North American adolescents of European descent, 71(t)
toxicity
“green tobacco sickness”, 77(fn 61)
use by adolescents, 69–75
age at initiation, 69
availability, 332, 332(fn 18)
A-D/HD and, 69
depression and, 69
girls, 69
age at menarche, 69(fn 46)
during pregnancy, 197
reasons for use, 226(fn 4)
high school students, 70
historical trends, 69(fn 47)
North American adolescents of African descent, 71
North American adolescents of European descent, 70, 71(t)
(see also: Nicotine; Treatment)
Tobacco Use Prevention Education, 333–334
Tolerance, vii(fign 1)
alcohol use and, 22
amphetamine use and, 52
benzodiazepine use and, 28
caffeine use and, 61
definition, 22
disruptive environment theory and, 135, 136
LSD use and, 96–97
MDMA use and, 93
nicotine use and, 83
PCP use and, 113
volatile solvent and inhalant use and, 40
(see also Physical Dependence)
Toluene, 6(t), 40
physical dependence, 40
psychological dependence, 40
teratogenesis and, 192
A-D/HD and, 192
embryopathy, 184, 192
similarity to FAS / FASD, 192
(see also: Chlorinated Hydrocarbons; Glue; Volatile Solvents and Inhalants)
“Toot” see Cocaine
Topamax® see Topiramate
Topiramate
combination therapy, 345
common adverse effects, 345
“off label” use for alcohol abstinence maintenance, 345
Tranxene® see Clorazepate
Treatment
acupuncture, 338(fn 28)
AA, 357–359
abstinence, 14(fn), 358, 358(fn 48)
as an adjunct to individual psychotherapy, 359
cognitive-behavioral theory of adolescent chemical dependency and,
148, 150
efficacy, 359, 359(fn 51)
limitations, 357(fn 46), 358(fn 49)
number of meetings attended, 358(fn 49)
meetings for adolescents, 359(fn 50, 51)
relapse prevention factors, 358
Serenity Prayer, 357(fn 46)
similar groups, 359
social form of treatment, 358, 358(fn 47)
spiritual characteristics, 357(fn 46)
twelve steps
list, 358(t)
use in juvenile correctional facilities,
359(fn 50)
biopsychosocial model of adolescent susceptibility to a substance abuse disorder
and, 165–166
cognitive-behavioral theory of adolescent chemical dependency and, 149–150
cognitive therapy, 349, 349(t)
effectiveness, 356–357
ego-self theory of substance dependence
and, 138
existential theory of drug dependence and, 136
general guidelines, 339(t)
initiatory model of drug abuse and, 145,
145(fn 7)
integrative family therapy model and, 163–164
life process program theory of natural recovery
and, 147–148
Meta-Interactive Model of Child and Adolescent Use of the Drugs and Substances of Abuse
components, 322(fig), 361
use to evaluate relapse prevention, 362
natural history of drug use from adolescence
to the mid-30s and, 130
noncompliance and dual diagnosis, 291
optimal treatment program components, 362(t)
pharmacotherapy, 338–348
for alcohol abstinence maintenance, 343–345
for alcohol withdrawal syndrome, 341–342
for benzodiazepine overdosage, 340–341
for cocaine withdrawal syndrome, 342
for dual diagnosis, 348
for nicotine maintenance, 347
for nicotine withdrawal syndrome, 342
for opiate analgesic abstinence maintenance,
345–346
for opiate analgesic maintenance, 346–347
for opiate analgesic overdosage, 340–341
for tobacco smoking cessation, 347–348
multimodal therapy and, 321(fig), 338(fn 27)
poor response and dual diagnosis, 291
psychotherapy/counseling, 348–357
right-brain model of adolescent substance abuse
and, 142
structural family systems theory, extended
and, 157–158
theory of object relations and adolescent compulsive drug use
and, 143–144
tertiary prevention, 320, 338–362
Alcoholics Anonymous, 357–359, 357(fn 46),
358(t)
efficacy, 321(fig)
multimodal approaches, 320–321, 321(fig)
pharmacotherapy, 338–348
psychotherapy and counseling, 348–357
relapse prevention, 359–361, 360(fig)
variables amenable to, 319(t)
therapeutic communities, 355–356
  abstinence, 356
  efficacy, 356
egalitarianism, 355
  goals, 355
  recommendations for improvement, 356
  staff members, 355(fn 44)
treatment mandated by juvenile justice system, 355
treatment of adolescents with dual diagnosis, 309–315
  approaches, 310–315
  *developmental biopsychosocial disease model*, 312
  *dual disorders recovery counseling*, 312–313
  family-based therapies, 313–314
  holistic model of treatment, 313
  individualized approaches, 314–315
  barriers, 309–310
  consequences of non-treatment, 291
  noncompliance, 291
  pharmacotherapy, 348
  therapeutic guidelines, 315, 315(t)
(see also: Prevention; Relapsed Use)
Trexan® see Naltrexone
Triazolam, 6(t)
  benzodiazepine withdrawal syndrome and, 28
  brand/trade names, 6(t)
  common street names, 6(t)
  respiratory arrest and, 29
  state-dependent learning and, 231, 231(fn 11)
  teratogenesis and, 189
(see also Benzodiazepines)
Trichloroethane, 6(t)
  products containing, 32–33
(see also Volatile Solvents and Inhalants)
Trichloroethylene, 6(t)
  products containing, 32–33
(see also Volatile Solvents and Inhalants)
Tridiagnosis, 291, 307–309, 308(fig)
  bisexual adolescent boys and young adults and, 291, 308
  definition, 291
  gays and, 291, 308
  homeless children and adolescents and, 291, 307
  lesbian adolescent girls and, 307
(see also: Dual Diagnosis; HIV)
3,4,5-Trimethoxyamphetamine, 90(t)
1,3,7-Trimethylxanthine see Caffeine
“Truck Drivers” see Amphetamines
“Tuss” see Hydrocodone
*TWEAK*, 286–288, 287(t)
  detection of AUDs among adolescents, 286
  recommendations, 288
  reliability, 288
  scoring, 287, 287(t)
  sensitivity, 287
  specificity, 287
Twelve-Step Programs see Alcoholics Anonymous
“Twenty-Five” see LSD
“Twisted Sticks”, 82(t)
(see also Tobacco, Smokeless, Dissolvable)
Tylenol #4®, 6(tn c)
(see also Codeine)
U
“Ukrainian Ditchweed” see Cannabis
Ukrainian Use of Opium as a Sedative or to Relieve Teething Pain, 216(fn 36)
Unintentional Childhood Poisonings, 213–218
  definition, 213(fn 32)
  nicotine and, 78
  paucity of data, 214
  psychodepressants and, 215–216
  alcohol, 215
  opiate analgesics, 215–216
  management, 216
  volatile solvents and inhalants, 216
  lack of context for data analysis, 216
  psychodelics and, 218
  cannabis, 218
  MDMA, 94, 218
  management, 218
  PCP, 113
  suicide and, 214
  trends, 214, 215(fn 34)
(see also Poisonings)
“Uppers” see Amphetamines
Use Patterns see Patterns of Drug and Substance Use
V
“V’s” see Diazepam
Valium® see Diazepam
Vanadom® see Carisoprodol
Vermont Anti-Smoking Campaign, 332
Versed® see Midazolam
Vicodin®, 6(tn d)
“Vikes” see Hydrocodone
“Vino” see Alcohol
Vivitrol® see Naltrexone
“Vitamin K” see Ketamine
Volatile Inhalants see Volatile Solvents and Inhalants
Volatile Solvents and Inhalants, viii, 6(t), 32–41
alcohol-like disinhibitory euphoria, 32, 37, 38
attraction to use, 33, 34, 40
burns, 39
chlorinated hydrocarbons, 32–33
classification, viii(t), 6(t)
commonly abused volatile solvents and inhalants, 34
definition, 32
factors promoting use by children and adolescents, 33, 40
fatal cardiac dysrhythmias, 39, 39(fn 45)
coronary artery spasm and, 39(fn 45)
fluorinated hydrocarbons, 32
general pharmacology, 37–41
high school student use, 33
incidence of use among adolescents, 33–34, 34(fn 40, 41, 42)
mechanism of action, 37
methods of administration/use, 34–35
most abused solvents and inhalants, 34
nonhalogenated hydrocarbons, 39(fn 45)
overdosage, 41 (see also poisoning)
poisoning, 34(fn 43), 38
reformulation, 37, 40(fn 47)
relationship with mental disorders, 36
signs and symptoms of use, 35(t)
sudden sniffing death see toxicities, sudden sniffing death
suffocation see toxicities, asphyxiation
teratogenesis and, 192
terminology used to indicate use, 35
tolerance, 40
toxicities, 37–41
acute toxicities, 37–40
fatalities, 38–40
accidental injuries, 39
asphyxiation, 39
sudden sniffing death, 39–40, 40 (fn 46)
chronic toxicities, 40
difficulties in establishing, 37–38, 37(fn 44)
involvement of boys, 38
volatile gases, 33
volatile solvents, 33–34, 34(fn 36)

use
by adolescents, 33–34
of African descent, 34(fn 41)
of Asian descent, 34(fn 41)
of Native descent, 34(fn 42), 36
by high school students, 33
FAS / FASD and, 36
mental disorders and, 299(t)
(see also: individual volatile solvents and inhalants; Psychodepressants)

Volcano® Forced-Air Vaporizer, 101
Vyvanse® see Lisdexamfetamine

W
“Wafer” see Methadone
“Wake-Ups” see Amphetamines
“Wannabe-Speed” see Methcathinone
“Weed” see Marijuana
“Weight Belt Cleaner” see 1,4-Butanediol
Wernicke’s Encephalopathy see Wernicke-Korsakoff Syndrome
Wernicke-Korsakoff Syndrome, 21–22(t), 22(tn a, b)
alcohol use and, 25, 232
etiology, 25
prognosis, 25
treatment, 25
“West Coast” see Methamphetamine
“Wet” see “Fry”
“Whippets” see Nitrous Oxide
WHO see World Health Organization
Wine see Alcohol
Withdrawal Syndromes, vii(fig 1)
alcohol withdrawal syndrome, 22
management, 25, 25(fn 28), 341–342
signs and symptoms, 24–25
benzodiazepine withdrawal syndrome, 28
signs and symptoms, 28, 28(fn 31, 32)
caffeine withdrawal syndrome, 61, 61 (fn 31)
signs and symptoms, 61
cannabis withdrawal syndrome, 108
factors affecting severity, 108
signs and symptoms, 108
cocaine withdrawal syndrome, 68
management, 342
GHB withdrawal syndrome, 31–32
management, 31–32
signs and symptoms, 31
methamphetamine withdrawal syndrome, 52
MDMA withdrawal syndrome, 93
nicotine withdrawal syndrome, 83–84
future research questions, 85
management, 342
signs and symptoms, 83–84
craving among girls, 84
intensity among adolescents with dual
diagnosis, 84
most common symptom among
adolescents, 83(fn 68)
relationship to nicotine blood concentra-
tions, 84, 84(fn 70)
opiate analgesic withdrawal syndrome, 10
management, 342(fn 30)
signs and symptoms, 13(t)
severity, 11(fn 13)
signs and symptoms, 341(fn 29)
(see also Physical Dependence)
World Health Organization (WHO)
development of the ASSIST, 259–260
development of the AUDIT, 261
documentation of injuries related to alcohol use,
248(fn 2)
Wyamine® see Mephentermine

X
Xanax® see Alprazolam
“Xannies” see Alprazolam
XR-NTX® see Naltrexone
“XTC” see MDMA
Xylene, 32
(see also Volatile Solvents and Inhalants)
Xyrem® see GHB

Y
“Yage” see Harmala Alkaloids
“Yaje” see Harmala Alkaloids
“Yellow” see Propoxyphene
“Yellows” see Pentobarbital

Z
Zaleplon
brand/trade names, 6(t)
(see also Z-Drugs)
Z-Drugs, 6(t)
brand/trade names, 6(t)
classification, viii(t), 6(t)
(see also Sedative-Hypnotics)
Zopiclone
brand/trade names, 6(t)
excretion in breast milk, 210(t)
(see also Z-Drugs)
Zopidem
brand/trade names, 6(t)
common street names, 6(t)
gamma-aminobutyric acid receptor complex and,
23(fig)
(see also Z-Drugs)
“Zzz” see Lorazepam